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ABSTRACT
BIOCHEMISTRY OF HEMOLYSIN TOXIN ACTIVATION BY FATTY 
ACYLATION: CHARACTERIZATION OF AN INTERNAL 
PROTEIN ACYLTRANSFERASE 
by
Michael Stephen Trent
Hemolysin toxin produced and secreted by pathogenic Escherichia coli is one of a family 
of cytolytic, structurally homologous protein toxins known as RTX (repeats in toxin) 
toxins. RTX toxins are products of a gene cluster, CABD. The A gene product, nontoxic 
hemolysin (proHlyA) i s made toxic by post-translational fatty acylation of two internal 
lysine residues. HlyC, C gene product, is essential for acylation, and acyl-acyl carrier 
protein (ACP) is the acyl donor. HlyB and HlyD are involved in secretion of the toxin. 
HlyC was thought to serve as an internal protein acyltransferase and remained 
uncharacterized until now.
ProHlyA and HlyC were separately subcloned, expressed, and purified, and acyl-ACPs 
with diverse radioactive acyl groups were synthesized. With these proteins, the 
conversion of proHlyA to HlyA by acyltransfer was assayed. Acyl-ACP was the obligate 
acyl donor. Acyltransfer was catalyzed by HlyC monomer, and an acyl-enzyme 
intermediate was detected and shown to catalyze the reverse reaction. The reaction 
mechanism was examined by steady state kinetics, and the nature of inhibitions by 
reaction products was determined. The kinetic mechanism of the internal protein 
acylation was compatible with an uni uni iso uni uni ping pong with isomerization of the 
F form of the enzyme.
Clues to the chemical mechanism for the acyltransferase were elucidated by both
chemical modification studies and site directed mutagenesis of the enzyme. Chemical
modification experiments ruled out any critical cysteines, serines, and lysine residues, but
suggested a role for histidine(s) and tyrosine(s) in acyltransferase function. In order to
iii
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examine the function of specific residues and possibly corroborate the chemical findings, 
site directed mutagenesis studies of the acyltransferase were empolyed. Seventeen 
residues that were conserved among 13 different RTX toxin acyltransferases were 
individually mutated, and the respective HlyCs expressed, and characterized. Residues 
that were critical for acyltransferase function included Gly 11, His 23, Tyr 70, and Gly 
85. As with chemical modification data, mutagenesis ruled out any conserved, essential, 
cysteines or serines critical for HlyC acyltransferase activity.
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CHAPTER 1 
INTRODUCTION
Pathogenic Escherichia coli secrete a toxic protein, hemolysin (HlyA), which 
binds to and lyses mammalian cell membranes and, at lower concentrations, perturbs cell 
signal transduction and release of inflammatory mediators. Approximately 50% o ff. 
coli causing extraintestinal infections in man produce HlyA, thus it is considered an 
important virulence factor ( I, 2). It is a member of a family of homologous cytolytic 
toxins produced by Gram negative bacteria. These newly discovered toxins are 
characterized by the presence of numerous glycine rich nine amino acid repeat units and 
have been labeled the RTX (repeat in toxin) toxins (3). In addition to their unique 
structural feature, the toxins share a Ca2+ dependency for cell lysis, a signal-peptide 
independent secretion mechanism, a common mode of activation, but they vary in target 
cell specificity. Various RTX toxins include: enterohemorrhagic 0157:H7 £. coli 
hemolysin (EhxA) (4), Bordetella pertussis bifunctional adenylate cyclase-hemolysin 
(CyaA), Pasteurella hemolytica leukotoxin (LktA), Actinobacillus 
actinomycetemcomitans leukotoxin (AaltAy), and Actinobacillus pleuropneumoniae 
hemolysins (ApxIA and ApxIIA) and leukotoxin (ApxIHA), with E. coli HlyA 
considered the prototype of the group (5).
The E. coli HlyA toxin arises from the expression of the hlyCABD operon located 
on either the bacterial chromosome or conjugative plasmids (d). The hlyA gene product 
is first synthesized as a 110 kDa inactive protoxin (proHlyA) that is post translationally 
modified by the hlyC gene product, HlyC (7). The acylation reaction occurs within the 
cytosol of the bacterium and requires HlyC for the transfer of a fatty-acyl group from
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2
acyl-acyl earner protein (acyl-ACP) to proHlyA, converting it to HlyA. Acyl-ACP is 
the obligate acyl donor with acyl-CoAs not serving as substrates in the reaction (8). Like 
acyl-CoA, the acyl group of acyl-ACP is attached to the protein via a thioester bond on 
the terminal sulfhydryl of a 4’-phosphopantethiene group that is attached to ACP via a 
phosphodiester bond to serine 36 (9). Acyl-ACP is a small (~9 kDa), acidic protein that 
was first discovered to function in the fatty acid biosynthetic pathways (9). Since then, 
acyl-ACP has been shown to function as an acyl donor in the synthesis of phospholipids 
(70), lipid A component of lipopolysaccharide (LPS) (77), membrane-derived 
oligosaccharides (72), and for the synthesis of lipoylated enzymes as lipoyl-ACP (73). 
After acylation, HlyA is secreted from the bacterium by the action of two specific inner 
membrane proteins, HlyB and HlyD, which are part of the hemolysin operon, and the 
outer membrane protein, TolC (14,15). Acylation is not essential for secretion (7), but 
acylation is the single factor that renders the protein toxic.
Although, the exact role of HlyC was not known when the present study began, it 
was assumed to function as an acyltransferase. The nature of in vitro HlyC-dependent 
modification of proHlyA was shown to be an internal acylation of the e-amino groups of 
lysine residues 564 and 690 forming amide bonds (76). The in vivo acylation pattern of £. 
coli hemolysin was shown to be the same as the in vitro activated toxin (77), but the 
nature of the fatty acid in  vivo remains unknown. The in vivo modification of CyaA, the 
adenylate cyclase toxin from Bordetella pertussis, was shown to be palmitoylation of the 
e-amino group of a single internal residue, lysine 983, corresponding to lysine 690 of 
HlyA (18). A summary of the HlyC-dependent HlyA activation by fatty acylation is 
shown in Figure I.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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proHlyA
Figure 1: E. coli hemolysin (HlyA) acylation and secretion. (CM, cytoplasmic 
membrane; OM, outer membrane) HlyA is expressed first as the inactive protoxin, 
proHlyA, which is activated by fatty acylation by the acyltransferase HlyC. Acyl-ACP 
serves as the acyl donor. HlyA is secreted through a sec-independent pathway by the two 
gene products o f the hemolysin operon, hlyB and hlyD, and one unrelated protein tolC.
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Once acylated and in the presence o f Ca2\  HlyA has the ability to bind and form 
cation-specific channels in target cells leading to osmotic lysis (79). The nature of cell 
lysis is not yet fully understood, and the finer points of the subject will not be discussed 
here. It seems to occur via a two-step mechanism: a reversible membrane adsorption step 
followed by an irreversible insertion (20), the latter requiring a change in HlyA 
conformation (27). It is assumed that membrane insertion is followed by toxin 
oligomerization within the host cell membrane leading to pore formation (22, 23).
HlyA is a powerful lytic agent, but also of great interest are host cell responses 
elicited at subhemolytic doses. For example, HlyA induces leukotriene production and 
phosphoinositide hydrolysis in human neutrophils (7), stimulates nitric oxide production 
in porcine endothelial cells (24), increases production of interleukin (IL )l-(i and tumor 
necrosis factor (TNF) in human monocytes (2); and induces the rapid and massive 
shedding of the LPS (CD 14) and the IL-6 receptors (25). In addition to these responses, 
HlyA and other RTX toxins have been shown to induce apotosis in human lymphocytes 
(26, 27).
The various RTX toxins differ in cell and host specificity and are divided into two 
groups, hemolysins and leukotoxins. For example, HlyA and the hemolysins ApxIA and 
ApxEA, have a wide range of specificity including erythrocytes and leukocytes o f 
animals and humans; whereas, the LktA and Aalt A leukotoxins have no effect on 
erythrocytes, but are powerful toxins for a narrow range of phagocytic cells of ruminants 
and humans, respectively (28). The differences in target cell sensitivity for the RTX  
toxins could be attributed to several reasons including target cell receptor recognition, 
membrane composition, and membrane repair mechanisms. Recently, Lally and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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colleagues showed evidence that the AaltA leukotoxin and HlyA bind to the CD1 la- 
CD18 integrin (lymphocyte function-associated antigen 1) on human cells, possibly 
functioning as a receptor (29).
HlyA toxicity is Ca2* dependent with the RTX toxin nonapeptide repeat unit 
(Leu-X-Gly-Gly-X-Gly-(Asn/Asp)-Asp-X) functioning as a Ca2*-binding motif via the 
negatively charged aspartate residues (30, 31). HlyA contains 11-17 repeat units, 
depending upon how much one adheres to the consensus sequence, between amino acids 
739 and 849 (32). Ca2+ binding is not dependent upon HlyC modification and the 
necessity of Ca2" for HlyA activity is not fully understood. Although Ca2+ binding has 
not been shown to induce a large conformational change in HlyA, there are associated 
changes in surface hydrophobicity in the Ca2" bound state (33) and Ca2~ induced 
conformational changes have been shown for CyaA (34, 35).
The hemolysin system provides a unique opportunity to study an internal 
acylation of a protein. Internal fatty acylation of proteins is recognized as a means of 
modifying protein behavior in biological regulatory mechanisms such as signaling, and 
many toxins exert their effects through distortion of cellular signaling mechanisms. 
Numerous instances of eukaryotic protein fatty acylation have been reported (36) and two 
classes of acylproteins are found in the literature. One is typified by 14 carbon myristic 
acid in an amide-linkage to the N-terminal glycine of the target protein following 
removal of the initiator methionine. The reaction is catalyzed by the ubiquitous 
myristoyl-CoA: protein N-myristoyl transferase and has been thoroughly characterized 
(37). The second group contains primarily hexa- or octadecanoic acids in ester linkages
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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with internal cysteine or threonine residues, and with less frequency in an amide linkage 
to lysine residues (38, 39).
The acyltransferases catalyzing these internal acylations have been elusive and 
remain for the most part uncharacterized; although, recently two protein palmitoyl 
acyltransferases that transfer palmitoyl groups to H-Ras and spectrin have been purified 
(40, 41). Palmitoylation of proteins at the thiol group of cysteine residues results in 
thioester bonds which are labile in nature, and a thioesterase that removes palmitate from 
H-Ras and Ga subunits has been cloned (42). Unlike a thiol ester, the amide linkage of 
acyl groups results in a stable lipid modification. HlyA and other members of the RTX 
toxin family are the only known prokaryotic proteins that are post-translationally 
modified by internal amide fatty acylation. There are four eukaryotic proteins that are 
known to have internal acylated lysine residues: TNF-a (43), IL -la , IL -ip  (44), and 
cytochrome c oxidase (45). Also, two integral membrane proteins, nicotinic 
acetylcholine receptor and the insulin receptor, are speculated to contain an internal 
amide linked fatty acid, but the sites of acylation are unkown (46, 47). In time, more 
internal amide-linked fatty acylations will emerge since metabolic labeling studies predict 
that only a fraction of acylproteins have been identified (48). None of the 
acyltransferases catalyzing internal amide acylations have been cloned, isolated, or 
characterized, leaving the characterization of HlyC a unique opportunity.
Comparison of the HlyC sequence to known acyltransferases via a BLAST search 
revealed no similarities and it has been reported that proHlyA and HlyC are produced in 
almost equimolar amounts (49), confusing the issue that HlyC functions as a catalyst. 
However, the common scheme of the RTX activation/acylation reaction is demonstrated
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by the fact that RTX C gene products can activate RTX toxins from different organisms, 
suggesting that the RTX acyitransferases function in a similar fashion. For example, the 
hemolysin of Actinobacillus pleuropneumoniae (ApxIA), the Pasteurella hemolytica 
leukotoxin (LktA), and the Bordetella pertussis adenylate cyclase toxin (CyaA) have all 
been activated by the E. coli HlyC acyltransferase (50,51, 52,53). An indirect, 
unstandardized assay of undefined stoichimetry has been used previously to monitor the 
function of the putative enzyme. Routinely, proHly A activated by HlyC was incubated 
with a suspension of erythrocytes in the presence of Ca2\  and the amount of hemoglobin 
released was monitored. Since the mechanism of hemolysis is unknown, the amount of 
proHlyA acylated cannot be determined by this method, and the two separate events, 
acylation and lysis cannot be measured independently.
The role of HlyC in acylation of proHlyA needed clarification. To address the 
issue of HlyC’s putative acyltransferase function, HlyC and proHlyA were subcloned into 
separate hyperexpression systems and purifed. Using purified, defined acyl-ACP (with 
radioactive acyl groups) and proHly A, the acyltransferase activity of HlyC was studied, 
and the enzyme characterized. The reaction under investigation is shown below.
proHlyA + [14C]acyl-ACP [,4C]HlyA + ACPSH
Such an assay enabled independent study of two significant and separate events, internal 
acylation of a protein and characterization of a toxin. The enzyme was fully 
characterized and evidence that HlyC functions as an acyltransferase is presented. 
Because Ca2+ is required for toxin function, the effects of Ca2+ on HlyA acylation were 
studied. The kinetic parameters of acyl-ACPs bearing diverse acyl groups were
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determined as well as the toxicities of the acyl-toxins they produced. Notably, HlyC 
formed a reactive acyl-enzyme intermediate, and the acyl-HIyC intermediate was able to 
catalyze the reverse reaction transferring the acyl group to ACPSH forming acyl-ACP.
The kinetic or chemical mechanism o f an enzyme catalyzing the internal acylation 
of a protein has never been determined. In the present study, the kinetic mechanism of 
the internal acylation of proHlyA catalyzed by HlyC was determined by steady state 
kinetics and by reaction product inhibition studies. Finally, chemical modification and 
site-directed mutagenesis of HlyC were used as tools to determine residues involved in 
the catalysis of the acyl transfer reaction contributing to the delineation of the chemical 
mechanism.
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CHAPTER 2 
MATERIALS AND METHODS
Biolpgicals and Reagents 
[ l - ,4C]labeled fatty acids, [1-I4C] palmitoyl-CoA, and [ l - 14C]sodium pantothenate 
were from New England Nuclear except for lauric acid which was from Amersham. 
American Radiolabeled Chemicals, Inc. supplied [9,10-3H] labeled palmitoleic acid. 
Palmitoyl-CoA was from P.L. Biochemicals. Novagen was the source of alkaline 
phosphatase conjugated S-peptide. Nitrocellulose, 0.4S pM, was from Costar. Spectrum 
Medical Industries, Inc. was the source of Spectra/Gel A4. Agar for DNA electrophoresis 
was from FMC. The following items were supplied by Fisher Scientific: 40% stock 
acrylamide:bisacrylamide (37.5:1) solution, hydroxylamine (NH2OH), dithiothreitol 
(DTT), isopropyl thiogalactoside (IPTG), sodium dodecyl sulfate (SDS), sodium 
deoxycholate, urea, chloramphenicol, kanamycin, tetracycline, ampicillin, bovine serum 
albumin, Spectra/Por dialysis tubing, bacto-tryptone, bacto-yeast extract and agar. N- 
ethylmaleimide (NEM), /7-chloromercuribenzoate (PCMB), phenylmethylsulfonyl fluoride 
(PMSF), 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), diethylpyrocarbonate 
(DEPC), tetranitromethane (TNM), phenylglyoxal (PG), thrombin, ribonuclease S-protein. 
Kodak film, dimethyl suberimidate, Coomassie brilliant blue R, and Tween-20 were from 
Sigma. EcoKV, deoxynucleotides, ammonium persulfate, 5-bromo-4-chloro-3-indoyl 
phosphate (BCIP), nitrobiue tetrazolium (NBT), N, N, N \ N',-tetramethylethylenediamine 
(TEMED), Wizard DNA Clean-Up System, Wizard Miniprep and Midiprep DNA 
Purification System were from Promega. New England Biolabs was the source of T4
9
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DNA ligase, calf intestinal phosphatase, Deep Vent DNA polymerase, Deep Vent 10X 
buffer, and Dpn I. Pfu Turbo DNA polymerase and XL-2 Blue Ultracompetent cells were 
from Stratagene. Protein molecular weight standards were from Bio-Rad, Novex, and 
New England Biolabs. High and low DNA mass standards were from Life Technologies. 
All chemicals were reagent grade.
Escherichia coli 
Novagen was the source of E. coli strains HMS174, BLR(DE3),
BLR(DE3)pLysS, BL21(DE3)pLysS, and NovaBlue cells. Permanent stocks of E. coli 
were stored at -80 °C as 8% glycerol stocks. The genotype of each strain is listed in 
Table 1. E. coli cultures were routinely grown in Luria broth (LB) (54) at 37 °C at 200 
rpm. Other bacterial growth media included M9 minimal media (54), 2XTY and TB 
medium (55). LB-agar plates were prepared by the addition of 20 g agar per liter LB 
medium. Growth media were supplemented with either kanamycin, tetracycline, 
chloramphenicol, or ampicillin with final concentrations of 34 pg/mL, 12.5 pg/mL, 34 
pg/mL and 50 pg/mL respectively.
Recombinant DNAs and Techniques
Preparation of Competent E. coli Cells
All bacterial strains used for the introduction of plasmid DNA were made 
competent by the calcium chloride method of transformation (56), except for the XL-2 
Blue strain which was purchased from Stratagene.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
11
Table I. E  COU  STRAIN GENOTYPE DESCRIPTIONS
Strain Genotype
HMS174 F  recA hsdR (nci2*mKi2~) Rif*
BLR(DE3) F  ompT hsdSe (rs'ma*) gal dcm A(srl-recA)306::Tnl0 (Tc*) A.
(DE3)
BLR(DE3)pLysS F  ompT hsdSa (rs'ma') gal dcm A(srl-recA)306. Tn 10 (Tc*) X 
(DE3) pLysS (Cmr)
BL21 (DE3 )pLy sS F  ompT hsdSB (ra'ma*) gal dcm X(DE3) pLysS (Cm1)
XL-2 Blue strain recAl endAl gyrA96 thi-1 hsdR 17 supE44 relAl lac [F  proAB 
laclqZAM15 TnlO (Tet1)  Amy Cam*]*
NovaBlue endAl hsdR17 (rKn'mKu ) supE44 thi-1 recAl gyrA96 relAl 
lacfF proA*B* laclqZAM15::TnlO (Tc^l
Transformation
The method for the introduction of plasmid DNA into E. coli host, except for the 
XL-2 Blue strain, was that outlined by the pET System Manual from Novagen (55). The 
method of transformation of XL-2 Blue E  coli was that outlined by the Epicurian Coli 
Ultracompetent and Supercompetent Instruction Manual from Stratagene. XL-2 Blue E. 
coli were only used for transforming PCR products prepared for the construction of 
mutant hfyCs.
Plasmid Purification
Plasmids containing the native HlyC or mutant hlyC genes were propagated in 
NovaBlue and XL-2 Blue E. coli strains respectively. The Wizard Miniprep and Midiprep 
DNA purification systems were used for the small-scale and large-scale isolations of 
plasmid respectively. These systems were used only when the resulting plasmid
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preparation was needed as template for DNA sequencing reactions, template for site- 
directed mutagenesis, or during vector preparation for subcloning. Isolation of plasmid 
DNAs from positive clones during subcloning of hemolysin genes were performed 
following a method outlined by the pET system manual from Novagen (55).
DNA Agarose Gel Electrophoresis
DNA electrophoresis was carried out using the Minicell EC370 electrophoretic gel 
system from Fisher Scientific. For routine analysis of DNA samples, samples were run on 
40 mM Tris-acetate, 1 mM EDTA (TAE) agarose gels and stained during electrophoresis 
by including ethidium bromide in the TAE electrophoresis buffer at 0.33 pg/mL. DNA 
samples were mixed with S0% glycerol solution containing 0.25% w/v bromophenol blue 
prior to application to the gel. Electrophoresis was routinely performed at 100 V and 
monitored by movement of the bromophenol blue. Excess ethidium bromide was removed 
by destaining in water for 20 minutes. The presence of DNA was visualized by UV- 
transillumination on a 312 nm variable intensity transilluminator. For preparation of DNA 
to be isolated from agarose gel slices for subsequent applications, no ethidium bromide 
was included in either the agarose gel or the electrophoresis buffer. To locate DNA to be 
isolated from the gel, an additional lane containing a duplicate sample was separated from 
the rest of the gel and stained for 20 min in TAE buffer containing ethidium bromide as 
described above.
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DNA Quantification
DNA was quantified by comparison to either low DNA (100 bp - 2000 bp) mass 
or high DNA (1000 bp -10,000 bp) mass standards electrophoresed along with samples of 
unknown concentrations.
Genetic Materials
Novagen was the source of pET plasmids. Dr. Colin Hughes provided the 
construct pEKSO (57) containing the MyCABD operon used to produce native (flyA.
Both pTXAl and pTXCl were prepared by Dr. Lesa Worsham in this laboratory and 
served as separate hyperexpression systems for proHly A and S-tag-HlyC respectively
(58).
Oligonucelotides
Oligonucleotides used for subcloning of the native hlyC gene, site-directed 
mutagenesis of hlyC, or for colony screening were purchased from Integrated DNA 
Technologies and are described in Table 2.
Construction of Recombinant His^-S-taa-HlvC
HlyC was expressed as a His«-S-tag fusion protein using pET30(a)+ and a 513 bp 
PCR product from pEKSO encoding HlyC. pET30a(+) vector treated with the restriction 
endonuclease £coRV, followed by treatment with calf intestinal phosphatase, was 
separated from remaining undigested pET30a(+) using a 0.7% agarose gel. Gel slices 
containing the digested vector were removed and the DNA isolated using a spin column. 
Vector was concentrated by precipitation with ethanol and sodium acetate (55,59). The
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Name* >\bSequence (S’ to 3’)
HlyC Upper 
HlyC Lower 
T7 Promoter 
GUA Upper 
G11A Lower 
S20A Upper 
S20A Lower 
H23A Upper 
H23A Lower 
H23C Upper 
H23C Lower 
H23S Upper 
H23S Lower 
R24A Upper 
R24A Lower 
C57A Upper 
C57A Lower 
S38A Upper 
S38A Lower 
E67A Upper 
E67A Lower 
Y70G Upper 
Y70G Lower 
Y70F Upper 
Y70F Lower 
S76A Upper 
S76A Lower 
G83A Upper 
G83A Lower 
D86A Upper 
D86A Lower 
R87A Upper 
R87A Lower 
Y150G Upper 
Y150G Lower 
Y150F Upper 
Y150F Lower
ATGAATATAAACAAACCATTAGAGATTCTT 
TTAACC AGTTAATG AAAAATTAAAATCTGA 
TAATACGACTCACTATAGGG 
CCATTAGAGATTCTTGCTCATGTATCCTGGCTATGGGCCAG 
CTGGCCCATAGCCAGGATACATGAGCAAGAATCTCTAATGG 
CCTGGCTATGGGCCAGTGCTCCACTACACAGAAACTGGCC 
GGCCAGTTTCTGTGTAGTGGAGCACTGGCCCATAGCCAGG 
GGCTATGGGCCAGTTCTCCACTAGCTAGAAACTGGCCAGTATC 
GATACTGGCCAGTTTCTAGCTAGTGGAGAACTGGCCCATAGCC 
GGCTATGGGCC AGTTCTCC ACTATGT AGAAACTGGCC AGTATC 
GATACTGGCC AGTTTCTACAT AGTGGAGAACTGGCCC ATAGCC 
GGCTATGGGCC AGTTCTCC ACTATCT AGAAACTGGCC AGTATC 
GATACTGGCCAGTTTCTAGATAGTGGAGAACTGGCCCATAGCC 
GGGCC AGTTCTCC ACT AC ACGCT AACTGGCC AGTATCTTTG 
C AAAGATACTGGCC AGTTAGCGTGT AGTGGAGAACTGGCCC 
GATT ACCCTGTCGCGTATGCTAGTTGGGCTAATTT AAGTTTAG 
CTAAACTTAAATTAGCCC AACTAGCATACGCGAC AGGGT AATC 
GATTACCCTGTCGCGTATTGTGCTTGGGCTAATTTAAGTTTAG 
CTAAACTTAAATTAGCCCAAGCACAATACGCGACAGGGTAATC 
GGGCTAATTTAAGTTTAGAAAATGCTATTAAAT ATCTTAATGATG 
CATC ATTAAGATATTT AATAGCATTTTCTAAACTTAAATTAGCCC 
GTTTAGAAAATGAAATTAAAGGTCTTAATGATGTTACCTCATTAG 
CTAATGAGGTAAC ATC ATTAAGACCTTTAATTTC ATTTTCTAAAC 
GTTTAGAAAATGAAATTAAATTCCTTAATGATGTTACCTCATTAG 
CT AATGAGGT AAC ATC ATTAAGG AATTTAATTTC ATTTTCTAAAC 
CTTAATGATGTT ACCGCTTT AGTTGC AGAAGACTGGACTTC AGG 
CCTGAAGTCC AGTCTTCTGC AACTAAAGCGGTAAC ATC ATTAAG 
GC AGAAGACTGGACTTC AGCTGATCGT AAATGGTTC ATTGAC 
GTCAATGAACCATTTACGATCAGCTGAAGTCCAGTCTTCTGC 
CAGAAGACTGGACTTCAGGTGCTCGTAAATGGTTCATTGACTGG 
CCAGTCAATGAACCATTTACGAGCACCTGAAGTCCAGTCTTCTG 
CAGAAGACTGGACTTCAGGTGATGCTAAATGGTTCATTGACTGG 
CCAGTCAATGAACCATTTAGCATCACCTGAAGTCCAGTCTTCTG 
GCGAATAAAATTTTTAAACAAGGTCACCACGAGTTAATAACTG 
C AGTT ATTAACTCGTGGTGACCTTGTTT AAAAATTTTATTCGC 
GCG AATAAAATTTTTAAAC AATT CC ACC ACG AGTT AATAACTG AAG 
CTTCAGTTATTAACTCGTGGTGGAATTGTTTAAAAATTTTATTCGC
‘Letters refer to one amino acid code. Codons shown in bold encode amino acid changes.
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DNA encoding for hlyC was prepared by PCR reactions (100 pL) containing 50 ng of 
pEK50 plasmid DNA as template, 10 pL of 10X Deep Vent Polymerase buffer, 4 mM 
Mg*2, 300 pM deoxynucleotides, 0.5 pM of phosphorylated HlyC upper and HlyC lower 
primers, and 2 U of Deep Vent Polymerase. The following PCR program was used: (i) 1 
cycle with 2 min at 95 °C, 58 °C for 45 sec, and 30 sec at 72 °C; (ii) 30 cycles with 45 sec 
at 95 °C, 45 sec at 58 °C, and 30 sec at 72 °C; and (iii) 1 cycle with 45 sec at 95 °C, 58 °C 
for 45 sec, and 5 min at 72 °C. PCR was performed using a GTC-2  GeneticThermal 
Cycler. Following amplification, the homogenous 513 bp product was processed through 
a Promega DNA Clean-Up Kit to remove unwanted polymerase and buffer contents.
The hlyC PCR product and vector were combined at a 1:3 ratio (vector:PCR 
product) and ligated using 2,000,000 units ligase per 20 pL reaction at 16 °C for 16 h.
The ligation reaction was transformed into NovaBlue cells and cells were screened for the 
presence and proper orientation of the hlyC gene using colony PCR (55). Colony PCR 
reactions (20 pL) contained colony lysate as template, 2 pL of 10X Deep Vent 
Polymerase buffer, 4 mM Mg*2, 300 pM deoxynucleotides, 0.5 pM of HlyC Lower and 
T7 promoter primer, and 0.4 U of Deep Vent Polymerase. The following PCR program 
was used: (i) 1 cycle with 2 min at 95 °C, 58 °C for 45 sec, and 43 sec at 72 °C; (ii) 30 
cycles with 45 sec at 95 °C, 45 sec at 58 °C, and 43 sec at 72 °C; and (iii) 1 cycle with 45 
sec at 95 °C, 58 °C for 45 sec, and 5 min at 72 °C. Positive screens gave a 700 bp PCR 
product. Plasmid DNA from positive colonies was transformed into BL2 l(DE3)pLysS 
cells for protein expression. The plasmid encoding for His6-S-tag-HlyC fusion protein was 
designated pTXC2.
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Construction of Mutant HlvCs
Site-directed mutations in hlyC were generated by a round circle PCR-based 
mutagenesis procedure (60) using the plasmid pTXC2 as the reaction template. Using one 
upper and lower primer for each mutation described in Table 2 led to the replication o f 
both plasmid strands with the desired mutation. For example, upper and lower H23 A  
primers were used to change His 23 to an alanine. The PCR reactions (SO pL) contained 
SO ng of pTXC2 plasmid DNA, S pL of 10X Pfu Turbo polymerase buffer, 200 pM  
deoxynucleotides, 2.S U of Pfu Turbo DNA polymerase, and 0.2 pM of one upper and 
lower primer for the desired mutation listed in Table 2. The following PCR program was 
used: (i) 1 cycle with 2 min at 9S °C, 55 °C for 1 min, and 12 min at 72 °C; (ii) 15 cycles 
with 45 sec at 95 °C, 55 °C for 1 min, and 12 min at 72 °C; and (iii) 1 cycle with 45 sec at 
95 °C, 55 °C for 1 min and 15 min at 72 °C. Following amplification of the mutated 
pTXC2 plasmid, 20 U of the dam methylation specific restriction enzyme, Dpn I, was 
added to each amplification reaction and incubated at 37 °C for 1.5 hrs to digest the 
parental, methylated (nonmutated template), supercoiled DNA. PCR reactions were 
applied to a 1% agarose gel, and the presence of a PCR product of ~ 6  kb was confirmed. 
To ensure complete digestion of the parental plasmid, a negative control PCR reaction 
containing everything but the mutagenic primers was also subjected to Dpn I  digestion. 
PCR reactions and negative controls were transformed into XL-2 Blue Ultracompetent 
cells from Stratagene. Individual colonies were screened, and plasmid DNAs from 
positive colonies transformed into BL21(DE3) pLysS cells. Recombinant DNA plasmids
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were designated pTXC2 with the mutation described afterward. For example, pTXC2 
H23A encodes for a His6-S-tag-HlyC with His 23 changed to alanine.
DNA Sequencing
Samples were sequenced using the T7 promoter primer except for the Y1SOF and 
Y150G mutants. For these constructs the HlyC upper primer was used in the sequencing 
reactions. Sequencing was done at the Molecular Genetics Facility at the University of 
Georgia on an A B I373 Stretch DNA Sequencer using the TAQ Dye terminator chemistry 
method (61, 62).
Protein Expression and Purifications
Expression and Purification of ProHlvA
ProHlyA was isolated from inclusion bodies in BLR(DE3)pLysS or BL21(DE3) 
pLysS cells containing pTXA l. Cells (200 mL culture) were grown in LB at 37 °C, 
induced with 1 mM IPTG at A<soo«« 0.6, and harvested 2 h later. Subsequent steps were at 
4 °C. Cells were harvested at 10,000 x g  for 10 min, resuspended in 5 ml of HED buffer 
[23 mM HEPES (pH 8.0), 5 mM EDTA, 2 mM DTT] and stored at -20 °C. Upon 
thawing, cells were exposed briefly to ultrasound. Inclusion bodies were collected by 
centrifugation at 20,000 x g  for 20 min and washed with 23 mL portions of the following 
solutions: 0.3% sodium deoxycholate in HED buffer, twice with 0.1% sodium 
deoxycholate in HED buffer, and finally three times with HED buffer without 
deoxycholate. ProHlyA was solubilized in 0.6 mL of HED buffer containing 6  M  urea for
1.3 h. Following centrifugation at 30,000 x g  for 30 min, the clarified solution was
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divided into aliquots and stored at -20 °C. Urea-containing buffers were always freshly 
prepared.
Secreted proHlyA was obtained from the supernatant solution of a 1.0 L 
BLR(DE3 VpTXA 1 culture. Cells were removed by centrifugation. ProHlyA was 
precipitated at 65% (NH^SC^ saturation and stirred for 16 h at 4 °C. After 
centrifugation at 25,000 x g for 30 min, the precipitate was washed with 0.2 M citrate (pH
3.0). The precipitate was dissolved in 3.0 mL of HED buffer containing 6  M urea and 
stored in aliquots at - 2 0  °C.
Expression and Purification of HlvCs
Cells (200 mL culture) for HlyC expression were grown in minimal media at 
37 °C, induced with 1 mM IPTG at Awomn 0 .6 , harvested 4-5 h later, resuspended, and 
stored in 5 mL o f HED buffer at -20 °C. HlyC was expressed as an S-tag or His6-S-tag 
fusion protein using pTXCl or pTXC2 respectively. The fusion protein was isolated at 4 
°C generally from inclusion bodies or occasionally from the soluble portion of cells. 
Thawed cells were briefly exposed to ultrasound. Soluble fusion protein was obtained 
from the cell lysate supernatant by centrifugation at 1 0 0 ,0 0 0  x g  for 1 h and stored at 
-20 °C. Alternatively, inclusion bodies from either pTXCl or pTXC2 cells were isolated 
from the cell lysate pellet (200 mL culture) collected by centrifugation at 20,000 x g  for 
20 min. Inclusion bodies were washed three times with 25 mL portions of HED buffer. 
The HlyC was solubilized by suspending the inclusion bodies in 15 mL of HED 6  M  urea 
buffer for 1.5 h. The fusion protein solution was clarified by centrifugation at 30,000 x g  
for 30 min. The solution was processed one of several ways:
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dialysis (8  Mr cutoff). The protein solution in 6  M urea was dialyzed against 1.0 L of 
HED 3 M and 1 M  urea buffers, each for 3 h, and finally against HED buffer for 16 h.
The solution was clarified by centrifugation at 30,000 x g  for 30 min. Fusion protein was 
precipitated overnight at 65% (NH«)2S0 4  saturation, collected by centrifugation at 30,000 
x g for 30 min, and dissolved in HED buffer. Protein was 2 mg.
To obtain highly purified S-tag-HlyC fusion protein from BL21(DE3)pLysS/ 
pTXCl cells, an S-protein affinity medium was used (63, 64). Fusion protein, 2 mg, was 
incubated overnight in 25 mM HEPES (pH 8.0), 0.15 M NaCl, 0.01% Triton X-100, 2 M  
urea with 1 mL of Spectra/Gel A4 which contained S-protein affinity ligand. The medium 
was washed with 50 mL of the same buffer followed by 30 mL 10 mM bisTris (pH 6.2),
0.15 M NaCl, 2 M urea. Fusion protein, 0.9 mg, was released from the affinity column 
with 100 mM glycine (pH 3.0), 2 M  urea and dialyzed against 25 mM MES (pH 6 .1), 2 M  
urea followed by HED 2 M urea buffer. Finally, it was freed of urea by dialysis against 
HED buffer and clarified by centrifugation at 30,000 x g  for 30 min.
To purify the His6-S-tag-HlyC, the protein was bound to an affinity His-Bind metal 
chelation resin containing immobilized Ni2* ions. His6-S-tag-Hly€ was isolated from 
inclusion bodies from 500 mL of BL21(DE3)pLysS/pTXC2 cells as described above. 15 
mg of protein in 7.5 mL of 20 mM Tris-HCl (pH 7.9), 0.5 M  NaCl, 5 mM imidazole, 6  M  
urea was applied to a 1.5 mL column of His-Bind resin at a flow rate of 10 column 
volumes/h. The column was washed with 20 mL of 20 mM Tris-HCl (pH 7.9), 0.5 M  
NaCl, 5 mM imidazole, 6  M urea followed by 20 mL of 20 mM Tris-HCl (pH 7.9), 0.5 M
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NaCl, 20 mM imidazole, 6  M  urea or until the A2S0 nm was <0.01. His6-S-tag-HlyC was 
eluted with 20 mM Tris (pH 7.9), 0.5 M NaCl, 500 mM imidazole, 6  M  urea. Urea was 
removed by stepwise dialysis as described above and the solution clarified by 
centrifugation at 30,000 x g  for 30 min. The purified His*-S-tag-HlyC was stored in 
aliquots at - 2 0  °C.
Expression and Purification of HlvA
HlyA was obtained from the supernatant solution of a culture of HMS174 
containing the plasmid pEK50 encoding for the complete hlyCABD operon. Cells were 
grown in LB to A«ooan 10 and centrifuged 10,000 x g for 10  min at 4 °C. Subsequent 
handling was at 4 °C. The solution was filtered through a 0.45 pm filter, and the filtrate 
was brought to 65% saturation with ammonium sulfate. The precipitate was processed 
like that described for secreted proHly A. HlyA was freshly prepared for each group of 
experiments and the preparations checked for viability at the time of use by erythrocyte 
lysis (described below).
Expression and Purification o f Acvl-ACPs
Radiolabelled acyl-ACPs were prepared using radioactive fatty acids. Acyl-ACPs 
were prepared by Dr. Lesa Worsham from E. coli ACPSH and acyl-ACP synthase (65, 66, 
67) as described by Trent and colleagues (58).
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Expression and Purification of f l- l4C1 ACPSH
ACPSH was isotopically labeled by adding 2 pM [ l- MC]sodium pantothenate (0.6 
pCi) (68, 69) to SO mL cultures of £  coli grown and processed to purify ACPSH as 
described (55). The purified ACPSH had a specific radioactivity of 0.3 Ci/Mol and was 
prepared by Dr. Lesa Worsham.
Protein Concentration 
Protein concentrations were measured by the Bradford assay (70).
Protein Gel Electrophoresis. Western Blotting, and Fluorographv 
SDS-PAGE followed the procedure of Laemmli (71). A Bio-Rad Semi-Dry 
Electrophoretic Transfer Cell was used according to the manufacturer’s instructions for 
Western Blots. Protein was transferred onto 0.4S pm nitrocellulose for 30 min at IS V. 
Autofluor from Midwest Scientific was used for fluorography. Gels were dried according 
to the manufacturer’s instructions using the Bio-Rad Gel Dryer and exposed to BioMax 
MR film using a Kodak Biomax Transcreen-LE Intensifying Screen.
Assay of Acyltransferase Activity 
The assay was done in microfuge tubes in a total volume of 100 pL in 100 mM 
HEPES (pH 8.0), 2 pM [ l4C]acyl-ACP, 22 pg proHly A (~2 pM), and HlyC (55 pg of 
soluble cell lysate, ~0.025 pM or 10 pg of protein extracted from inclusion bodies, ~2 
pM). The urea concentration did not exceed 0.4 M. Reaction was started by the addition 
of [uC]acyl-ACP. Following a 5 min incubation at 4 °C, reaction was stopped by placing 
the tubes in an 80 °C bath for twenty min. Enzyme was inactivated immediately; however,
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longer incubation at 80 °C was shown to enhance the precipitation of the [l4C]acyl- 
HlyA. 233 pL of saturated (NH4>2S0 4  in 500 mM Tris (pH 7.0) was added to achieve 
70% saturation. After 30 min at 4 °C, precipitated protein was collected by centrifugation 
at 13,600 x g  for 5 min. Acyl-ACP does not precipitate under these conditions. The 
pellet was washed and vortexed with 500 pL 50% isopropanol, and the precipitate was 
collected and dissolved in 1 mL of 0.2 M NaOH. The radioactivity of a 0.9 mL aliquot 
was measured in 5 mL of Ultima Gold Scintillation fluid.
In some cases, -2  pM native and mutant HlyCs were assayed by a quick dilution 
method. For these reactions, enzyme isolated from inclusion bodies was immediately 
diluted in 25 mM Hepes (pH 8.0) until the urea concentration was 0.4 M. The protein 
was incubated on ice for 25 min, followed by the addition of the substrates, proHlyA and 
[uC]acyl-ACP, and assayed as described above.
Kinetic Mechanism o f HlvC
Determination of Kinetic Parameters
Reaction velocities were measured using the assay described above under 
conditions where rates were linear with time. Kinetic data were analyzed using a 
computer program previously described (72) which calculated kinetic parameters by 
several different methods and by the nonlinear regression analysis of Wilkinson (73); the 
different methods of computing kinetic constants agreed with R values greater than 0.96. 
or else the data were rejected. Reported kinetic constants for the different acyl-ACP
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substrates were those computed from the Direct Linear analyses (74) using the 
nonlinear regression analysis of Wilkinson (73).
Steady State Kinetics and Product Inhibition Studies
Reaction velocities and kinetic data were determined as described above. The 
different methods of computing kinetic constants agreed giving R values greater than 0.97 
except for product inhibition experiments that contained both proHlyA and HlyA. At 
higher concentrations proHlyA and HlyA have a tendency to aggregate (75, 76), and R 
values in these circumstances ranged from 0 .91 to 1. Description of kinetic data plots are 
given in the individual figure legends.
Product inhibition studies were performed as described above except for those 
containing HlyA. Assays in which HlyA product inhibition was measured contained 1.5 M  
urea, in order to discourage aggregation of HlyA; this concentration of urea had no 
detectable effect on the other proteins in the assay.
Chemical Cross-Linking of Proteins Involved in ProHlvA Acvlation and Acyl-Enzvme
Intermediate Formation 
The reaction was set up as described above for assay of acyltransferase activity 
with the cross linking reagent, dimethyl suberimidate (DMS), added last. Any variations 
in substrates are given in Figure legends 2, 32, and 33. The reaction mixes were exposed 
to 10 mM DMS for 10 min at 2S °C. Chemical cross-linking was halted by the addition of 
1 M ammonium acetate to a final concentration of 100 mM, and proteins were 
precipitated at 4 °C with 10% trichloroacetic acid. After I h, precipitated protein was
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collected by centrifugation at 13,600 x g  for 5 min, washed with 500 pL acetone, and 
the pellet collected by centrifugation. Protein was dissolved in 20 pL 8  M  urea + 20 pL 2 
% SDS sample buffer and subjected to SDS-PAGE followed by fluorography. For acyl- 
enzyme intermediate formation for both native and mutant HlyCs, protein mixes were 
incubated for 10 min at 4 °C without DMS. Protein was precipitated with trichloroacetic 
acid and processed as described above.
Assay for the Formation of Acvl-f UC] ACPSH from Acvl-HlvC and [l4Cl ACPSH 
acyl-ACP + HlyC <-> [HlyC •  acyl-ACP] <-> acyl-HlyC + ACPSH 
The assay for the transfer of a long chain fatty acyl group from the enzyme 
intermediate, acyl-HlyC, to radiolabeled ACPSH as described by the equation above was 
as follows: Using the HlyC assay conditions described above, unlabeled myristoyl-ACP, 
25 p M , was incubated with either 25 or 50 pM HlyC for 10 min at 4 °C in order to form 
the putative reaction intermediate, unlabeled acyl-HlyC. The reverse reaction was begun 
by the addition of 25 pM [,4C]ACPSH followed by a 10 min incubation at 4 °C.
Following reaction, samples were made 10% in trichloroacetic acid and kept on ice for 45 
min then centrifuged at 13,600 x g  for 5 min. The protein pellet was washed with 500 pL 
of cold acetone, dissolved in 25 pL 8  M  urea + 20 pL 2% SDS sample buffer, and 
subjected to 15% SDS-PAGE followed by fluorography. Control reactions, which were 
processed identically, included the following combinations: 25 pM myristoyl-ACP + 25 
pM [UC] labeled ACPSH; 50 pM HlyC + 25 pM [WC] labeled ACPSH; and 25 pM [UC] 
labeled ACPSH.
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pH Activity Studies
Acyltransferase acitvity was assayed at a variety of pHs as described above using a 
Mes, Hepes, Tris, Glycine buffer system. Buffers were mixed together and used as a 
single buffer system titrated to the desired pH. All buffers in the assay were at a final 
concentration of 100 mM and NaCl was added to maintain an ionic strength of 0.52 M.
Chemical Modification of HlvC 
Chemical modifications of HlyC with a variety of group specific reagents were 
carried out primarily according to published procedures (77). The modification reactions 
were imitated by the addition of freshly prepared chemical reagents in a particular solvent 
to S-tag-HlyC isolated from inclusion bodies as described above. For each modification 
reaction, a control reaction was subjected to the same treatment with solvent only. All 
results were expressed as the percentage of the control activity. For each chemical 
modification reaction, the reagent was either removed by physical means or the reaction 
quenched as described below. Controls were done to ensure that the chemical modifier 
was completely removed before assay.
Modification bv N-ethvlmaleimide (NEM1 p-Chloromercuribenzoate (PCMB’l
A 260 mM solution of NEM was prepared in water and the concentration 
determined by measuring the Ajo2 «  using an extinction coefficient o f620 M 'lcm' 1 (78). A 
1 mL protein solution (2.5 mg) in 0.1 M  KPO4 (pH 7.0) buffer containing S-tag-HlyC was 
treated with 1.0 mM NEM at 25 °C for 15 min. Excess reagent was removed by 
application of the reaction to a 10 mL Sephadex G-25 fine column equilibrated in 25 mM
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Hepes (pH 8.0) buffer. Protein was eluted with 25 mM Hepes (pH 8.0) buffer 
containing 0.1 M  NaCl. Fractions were measured for A210»  and a portion of the peak 
fraction (-10  fig protein) assayed for acyltransferase activity.
A stock solution o f PCMB was prepared by dissolving the solid in 0.1 M  Tris (pH
11.0) buffer, followed by centrifugation at 30,000 x g  for 30 min to remove insoluble 
material. A 10 mM PCMB working solution was prepared by diluting a portion of the 
stock solution in 0.01 M  KPO4 (pH 7.0) buffer. The concentration of the PCMB solution 
was determined by measuring the A233 •»> using an extinction coefficient of 1.69 x 104 
M’lcm'1 (78). 100 pL of a 2.1 pg/pL HlyC solution in 20 mM Mes (pH 6.0) buffer was 
exposed to 1.0 mM PCMB by addition of a portion of a 10 mM PCMB solution.
Reaction proceeded for 10 min at 25 °C, and the excess reagent was removed using a 
centricon with a 5,000 MW cut-off. Following washing with 300 pi of HED buffer, 10 pg 
of modified protein was assayed for acyltransferase activity.
Modification bv Phenvlmethvlsulfonvl Fluroide (PMSF1 and 4-(2-Aminoethvn- 
benzencsulfonvl Fluoride (AEBSF1
Ten mM solutions of PMSF and AEBSF were prepared by dissolving the solids in 
dry isopropanol and dimethyl sulfoxide respectively. For both inhibitors, a 1.37 pg/pL 
HlyC solution in 100 pL of 25 mM Hepes (pH 8.0) was modified by 1.0 mM of the 
reagent for 10 min at 25 °C. Following reaction, the reagents were removed using a 
centricon with a 5,000 MW cut-off and the sample washed with 300 pi of HED buffer. 
Ten pg of protein was assayed for acyltransferase activity.
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Modification bv Diethvlpvrocarbonate (DEPO
A 65 mM DEPC stock solution was prepared in acetonitrile. The concentration of 
the reagent was determined by reaction with 10 mM imidazole in 0.1 M  KP04 (pH 6.0) 
buffer and measuring the increase in A24o«i using an extinction coefficient of 3200 M '1cm'1 
for the modified imidazole derivative (79). A 22 pL 2.0 pg/pL HlyC solution in 0 .1 M  
KPO4 (pH 6.0 or pH 8.0) buffer was exposed to various amounts of DEPC at 25 °C for 
10 min and the reaction quenched by the addition of a 20-fold molar excess of imidazole in 
0.1 M KPO4 (pH 6.0 or pH 8.0) buffer. To measure the modification reaction over time, 
a larger reaction was prepared, and at timed intervals, 10 pg aliquots containing enzyme 
were removed, quenched, and assayed. The presence of imidazole had no effect of 
acyltransferase activity.
Hvdroxvlamine (NH>OH 1 Treatment of Modified HlvC
Following treatment with 2 mM DEPC and quenching as described above, 2 M  
NH2OH (pH 7.0) was added to a final concentration of 100 mM. At various time 
intervals, 10 pg aliquots of enzyme were removed and assayed as described above. 
Activity was expressed as the percentage of a control HlyC sample (10 pg) treated with 
acetonitrile and 100 mM NH2OH for 240 min.
Modification bv Tetranitromethane (TNM)
Modification of HlyC by TNM was carried out by the addition of various amounts 
of an ethanol solution of the reagent (10 mM) to a 100 pL solution of enzyme at 0.95 
pg/pL in 0.05 M  Tris (pH 8.0) or 0.1 M  KPO4 (pH 6.0) buffers at 25 °C. Reactions were
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quenched by the addition of a 20-fold molar excess of L-tyrosine in 0.05 M  Tris (pH
8.0) buffer and 10 pg of modified enzyme assayed as described above. To measure the 
modification reaction over time, a larger reaction was prepared, and at timed intervals, 10 
pg aliquots of enzyme were removed, quenched, and assayed. The presence of excess 
tyrosine had no effect on acyltransferase activity.
Modification with N-acetvlimidazole (NAD
NAI was prepared from acetic anhydride (100 mmol) and imdiazole (87 mmol) as 
described by Staab and Rohr (80). The product was dissolved in warm acetone and 
precipitated with the addition of petroleum ether and the crystals dried and stored 
dessicated at -20 °C. Concentration of the reagent in acetonitrile was determined 
spectrophotometrically at 240 nm using an extinction coefficient of 3200 M*1 cm*1.
Chemical modification of HlyC by NAI was carried out by the addition of a freshly 
prepared acetonitrile solution of the reagent (100 mM) to a 50 pL 0.2 pg/pL enzyme 
solution in 50 mM Hepes (pH 7.5). The reaction was performed for 30 min at 25 °C. 
Following modification, the reagent was removed by 70% (NH^SC^ precipitation and the 
enzyme dissolved in 25mM Hepes (pH 7.0) buffer. 10.0 pg of modified HlyC was 
measured for acyltransferase activity at a pH of 7.0.
Modification with Phenvlglvoxal (PG)
A 200 mM solution of PG was prepared in 25 mM Hepes (pH 8.0) containing 50% 
ethanol. The reagent was added to a 50 pL, 0.2 pg/pL, HlyC solution in 25 mM Hepes 
(pH 8.0) buffer at 25 °C for one hour. Reactions were quenched by the addition of 20-
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fold molar excess of L-arginine in 25 mM Hepes (pH 8.0) and 10 pg of modified 
protein assayed for acyltransferase activity. Excess arginine had no effect HlyC activity.
Substrate/Product Protection Studies
Chemical modification protection experiments were performed by incubating 10 
pg of enzyme solution in 100 pi of HED buffer for 5 min with either 2 pM unlabeled 
myristoyl-ACP or ACPSH followed by chemical modification by one of the reagents 
described above. Enzyme was treated with either 2 mM DEPC, 5 mM PG, or 50 fold 
molar excess of TNM (0.22 mM). Prior to assay, samples were precipitated at 70% 
(NH^SC^ saturation at pH 7.0 at 4 °C and the enzyme was collected by centrifugation. 
Neither acyl-ACP nor ACPSH precipitates under these conditions, therefore any species 
of ACP were removed. The enzyme was then assayed using [ l- wC]myristoyl-ACP as 
described above.
Spectral Studies
Modification of HlyC by DEPC or TNM was monitored spectrally using a HP 
8452A Diode-Array Spectrophotometer at wavelengths ranging from 200-500 nm at 2 nm 
increments. For both reactions, a double sectored cuvette was used with the enzyme 
solution placed in the first sector and the modifying reagent placed in the second. For 
DEPC modification, a 1.0 mg/mL HlyC solution in 0.1 M  KP04 (pH 6.0) was modified 
with 1.0 mM DEPC at 25 °C. A spectrum was taken before mixing of the two solutions 
that served as the blank. Reactions were initiated by mixing the contents of the two 
sectors by inversion of the cuvette and spectra taken at various time intervals. For study
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of spectral changes attributed to TNM modification, a 2.72 mg/mL HlyC solution in 
0.05 M  Tris (pH 8.0) was modified with a 50-fold molar excess of TNM  (6.0 mM) at 25 
°C. A spectrum was taken before mixing and one 30 min after initiation of reaction. For 
both spectra, 0.05 M  Tris (pH 8.0) buffer served as the blank.
Characterization of HlvC Mutants 
Mutant HlyCs were purified from inclusion bodies as described above. Mutants 
were characterized like the native HlyC by performing chemical cross-linking reactions, 
detection of acyl-enzyme intermediate, and determination of Km and V™  for both 
proHlyA and myristoyl-ACP substrates as described above.
Assessment o f HlvA Lvtic Capability 
HlyA as an agent of erythrocyte lysis was measured in 0.05% suspensions of 
erythrocytes as described (81). Assays of proHlyA activation were done as described 
above except the reaction was stopped with 300 mM DTT which destroyed the thioester 
acyl donors. A dose-response curve was obtained for each separate acyl-HlyA formed 
from the corresponding acyl-ACP. In order to compare lytic capabilities of the separate 
acyl-HlyA’s, 20 pL aliquots of enzyme assay reaction mixtures immediately after 
completion and cessation of reaction, each containing a different acyl-ACP, were assayed 
for erythrocyte lysis.
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CHAPTER 3 
RESULTS
Expression and Purification of Proteins 
ProHlyA was expressed using recombinant DNA (pTXA l) containing the 
HlyABD genes. Expression of proHly A was independent of different growth conditions. 
Figure 2 lane 2 shows proHly A, Mr 107,000, present in the lysate o f cells which 
contained pTXAl while it was absent in cells which contained the vector, lane 3. As 
anticipated, since pTXAl encodes for HlyB and HlyD, proHly A was also isolated from 
the culture medium (lane 1). Intracellular proHly A was in inclusion bodies. Urea 
extraction of the isolated and washed inclusion bodies resulted in a preparation estimated 
by densitometry to contain >90% proHly A (lane 4). The protein was stored in 6 M urea 
and was stable at -20 °C for greater than 6 months. Each liter o f culture yielded -10-12 
mg of proHly A from inclusion bodies and 1.5 mg of proHly A from the cell culture 
media.
HlyC was either expressed as an S-tag or His6-S-tag fusion protein using pTXC 1 
or pTXC2 respectively. The highest yields of HlyC were obtained from cultures grown 
in minimal media at 37 °C harvested five hours after induction with 1 mM IPTG. 
Approximately, 60 mg of HlyC was expressed per liter of cell culture. The S-tag-HlyC 
fusion protein was seen in SDS-PAGE of the total cell lysate as an intensely staining 
band at Mr 22,500 (Figure 3 A lane 3) localized mainly in the insoluble portion of the cell 
lysate (lane 1) while a small amount was present in the soluble portion (lane 2). A lysate
31
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Figure 2: ProHlyA expression and purification. An SDS-10% PAGE showing 
distribution and purification of proHlyA. The arrow marks the position of the 107 kDa 
proHlyA. The gel was loaded as follows: lane 1, 10 pg o f protein from the 
BLR(DE3)pTXAl cell growth supernatant solution; lane 2, 10 pg of the 
BLR(DE3)pLysS/pTXAl cell lysate; lane 3, lOpg of lysate from cells that did not 
contain pTXAl; and lane 4 ,2  pg of proHlyA purified from inclusion bodies. The 
migration of mass markers is indicated on the left in kDa.
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Figure 3: Expression of S-tag-HlyC. An SDS-15% PAGE (A) and its western blot 
probed with S-protein alkaline phosphatase conjugate (B) showing the cellular 
distribution of S-tag-HlyC fusion protein. Lanes in A contained 10 pg of protein from 
the following sources: lane 1, insoluble fraction o f cell lysate; lane 2, soluble fraction of 
the cell lysate; lane 3, cell lysate; lane 4, lysate o f cells without pTXCl. The gel in B was 
loaded with the following proteins: lane 1, 3 pg of lysate o f cells lacking pTXCl; lane 2, 
1 pg of insoluble fraction of cell lysate; lane 3, 3 pg of the soluble fraction of the cell 
lysate; lane 4, 1 pg of the cell lysate. More protein was loaded into lanes 1 and 3 in order 
to visualize the fusion protein, if it were present. The migration of molecular mass 
markers is indicated on the left in kDa. The arrow shows the position of the fusion 
protein at 22.5 kDa for both the stained gel and western blot.
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of cells lacking the recombinant DNA (lane 4) contained none. A Western blot of the 
separated proteins (Figure 3B) confirmed the presence of a small amount of the fusion 
protein in the soluble fraction which reacted with the S-peptide-conjugate probe (lane 3). 
No fusion protein appeared in lysates of cells which did not contain pTXCl (lane 1) or 
which were not induced (not shown). The two dark bands (lanes 2 and 4) of the western 
blot (Figure 3B) confirmed the identity of the intensely stained Coomassie Blue bands 
(Figure 3 A, lanes 1 and 3) as S-tag-HlyC fusion protein. Densitometric analysis 
indicated that >50% of the insoluble protein was the fusion protein. Cellular location and 
expression of the His6-S-tag-HlyC from pTXC2 was identical to that of S-tag-HlyC from 
pTXCl. HlyC activity was assayed as described subsequently; sources of active enzyme 
included cell lysates, the 100,000 x g  solution of the cell lysate, and urea extracts of 
washed inclusion bodies.
Characterization of HlvC-Dependent ProHlvA Activation 
ProHlyA acylation was measured using defined quantities of purified substrates 
(proHlyA and [uC]palmitoyl-ACP) and isolated enzyme (HlyC) under reproducible 
reaction conditions. Radioactivity was transferred from acyl-ACP to proHlyA to form 
HlyA in the presence o f HlyC. With proHlyA, and palmitoyl-ACP concentrations each at 
2 pM and HlyC about 25 nM in the assay, about 1,500-3,000 dpm were obtained 
routinely. Assay blanks which contained heat-denatured HlyC measured about 50 
counts/min. HlyC source was 50 pg soluble protein of the cell lysate, and its 
concentration was estimated from western blot analyses and Novagen S-tag rapid assay
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kit. The specific activity of the cell extract soluble HlyC was -200 nanomoles fatty acyl 
group transferred/min/mg protein where HlyC was -0.1%  of the protein. In the absence 
of the recombinant hlyC or its expression, there was no proHlyA-acyl-ACP 
acyltransferase activity.
Fluorography of SDS-PAGE of the assay precipitates (Figure 4) showed the 
transfer of the radioactive fatty acyl group from palmitoyl-ACP (lanel) to a 107 kDa 
protein, HlyA (lane 5). There was no residual radioactivdy labeled palmitoyl-ACP 
following reaction termination and washing (lane 5). HlyA was labeled only when cell 
lysate containing HlyC was present; cell lysate without HlyC did not cause any transfer 
of radioactivity from acyl-ACP to proHlyA (lane 2). Reactions containing only HlyC and 
acyl-ACP or proHlyA and acyl-ACP (lanes 3 and 4 respectively) formed no HlyA. 
Densitometric analyses of fluorographs of HlyA formed in assays paralleled the assay of 
radioactivity incorporated into HlyA.
To verify that HlyC was responsible for the acyltransferase activity, both the S- 
tag-HlyC and the HiS6-S-tag-HlyC fusion protein were solublized from washed inclusion 
bodies (Figure 5 A lane 3 and Figure 5B lane 2) in buffered 6 M urea and affinity purified. 
S-tag-HlyC was applied to S-peptiae-iiganded Sepharose 4A. Following washing, 
elution at pH 3.0, and renaturation by dialysis to HED buffer the fusion protein was seen 
as a single band at M r 22,500 in Figure 5A, lane 4. -0.4 mg/L of culture of pure S-tag- 
HlyC was obtained by this method. His6-S-tag-HlyC from inclusion bodies (Figure 5B 
lane 2) was applied to an affinity His-Bind metal chelation resin containing immobilized 
Ni2+ ions. Following washing and elution with 500 mM imidazole, the His6-S-tag-HlyC
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Figure 4: Dependence of acyl-ACP-proHlyA acyl transfer on HlyC. Fluorography of an 
SDS-12% PAGE of redissolved assay precipitates showing the transfer of radiolabeled 
fatty acid from acyl-ACP (Mr -9,000) to proHlyA forming radiolabeled HlyA (Mr 
107,000). The method was that of Worsham and colleagues (82), and Kodak X-OMAT 
LS film was used. Although acyl-ACP does not precipitate under the conditions used to 
separate the reaction product HlyA, any entrapped thiol esters were removed by 
dissolving the assay precipitates in 100 pi 25 mM HEPES (pH 8.0), 1 mM DTT, 5 mM 
EDTA, 5 M urea and treated with 100 pi 2 M NH2OH (pH 10.0) for 30 min at 37 °C. 
Following precipitation with cold trichloroacetic acid, samples were dissolved in SDS- 
PAGE sample buffer. [ l -u C]palmitoyl-ACP, 0.4 pg, was applied to lane I; other lanes 
contained material from assays. Lane 2 assay contained proHlyA, acyl-ACP, and lysate 
from cells which did not contain pTXCl. Lane 3 assay contained acyl-ACP and 
BLR(DE3)pLysS/pTXCl cell lysate. Lane 4 assay contained proHlyA and acyl-ACP. 
Lane 5 assay contained acyl-ACP, proHlyA and BLR(DE3)pLysS/pTXCl cell lysate.
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Figure 5: Purification o f S-tag- (A) and (B) His6-S-tag-HlyC. (A) SDS-15% PAGE 
illustrating the S-tag-HlyC purification as described in the text. Proteins from the
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Figure S (continued): following sources were loaded in S pg aliquots: lane 1, mass 
standards in kDa; lane 2, unwashed inclusion bodies; lane 3, washed inclusion bodies; 
lane 4, pH 3.0 eluate from S-protein affinity chromatography; lane S, TSK-250 HPLC 
(Figure 7) peak fraction of acyl- ACP-proHly A acyltransferase activity. (B) SDS-15% 
PAGE illustrating the His6-S-tag-HlyC purification as described in the text. Proteins 
from the following sources were loaded in 10 pg aliquots: lane 1, mass standards in kDa; 
lane 2, washed inclusion bodies; lane 3, flow through; lane 4, 20 mM imidazole wash; 
lane S, 500 mM imidazole eluate from the His-Bind metal chelation resin.
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fusion protein electrophoresed at a Mr o f23,000 as shown Figure SB lane S. The yield of 
pure HlyC by this method was ~8 mg/L of culture. The purified HlyC from the 
imidazole elution was renatured by dialysis against HED buffer. The pure His6-S-tag- 
and S-tag-HlyCs both possessed acyl-ACP-proHlyA acyltransferase activity. The 
activities and stabilities of these preparations is discussed below.
The fused tags attached to the N-terminus of HlyC did not influence 
acyltransferase activity. The acyl- ACP-proHlyA acyltransferase activities o f two aliquots 
of soluble S-tag-HlyC from cell lysate were measured. One aliquot contained fusion 
protein while the other had been treated with thrombin to cleave the fusion protein to 
HlyC and S-tag. Fusion protein cleavage was monitored by S-peptide-conjugate probes 
of Western blots of SDS-PAGE. Exposure to thrombin overnight at 4 °C or for 2 h at 
25 °C resulted in disappearance of S-peptide-probe reactivity upon SDS-PAGE Western 
blots (data not shown). S-tag or His6-S-tag-HlyC fusion proteins and HlyC resulting 
from thrombin cleavage showed the same amount of acyltransferase activity.
A demonstration of the thrombin cleavage is shown in Figure 6. An S-peptide 
probe of an SDS-PAGE western blot shows the purified S-tag-HlyC (Figure 6B, lane 5); 
following exposure to thrombin, the S-tag was removed by proteolytic cleavage (lane 4). 
A Coomassie stained gel o f the same material is shown in lanes 2 (after thrombin 
treatment) and 3 (before thrombin treatment). A barely visible band near the 32.5 kD 
molecular weight marker is thrombin. The removal of the S-tag and its thrombin 
cleavage site changed the Mr of the protein band from 22,500 to -19,000, the size of 
HlyC monomer deduced from its DNA sequence (18,458).
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Figure 6: Thrombin Cleavage of S-tag-HlyC. SDS-15% PAGE and Western blot 
showing thrombin cleavage of S-tag-HlyC fusion protein. Proteins in lanes 1-3 were 
stained with Coomassie Blue, and proteins in lanes 4 and 5 were Westem-blotted and 
probed with S-peptide-alkaline phosphatase conjugate. Lane 1, mass standards in kDa; 
lanes 2 and 3 each contained 5 pg of fusion protein, lane 2 after treatment with thrombin 
and lane 3 before treatment. Lanes 4 and 5 were each loaded with 1 pg of fusion protein 
after and before exposure to thrombin, respectively.
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Table 3. COMPARISON OF HLYC ACYLTRANSFERASE ACTIVITIES
Source of HlyC Specific Activity*
100,000 x g supernatant of cell lysate 200,000
Urea Extracts of Washed Inclusion Bodies 502
Eluate from S-Protein affinity resin (Pure S-tag-HlyC) 278
Eluate from His-bind resin (Pure HiS6-S-tag-HlyC) 1100
*units are pmol of fatty acyl group transferred/min/mg protein
Although the eluate from the S-protein affinity resin resulted in a highly purified 
and active fusion protein, the relatively harsh conditions of purification and renaturation 
lowered the specific activity compared to that of soluble HlyC which had never been in 
inclusion bodies nor exposed to urea. A more active preparation of HlyC from 6 M urea 
was obtained by step wise removal of the denaturant by dialysis. The specific activity of 
the resulting enzyme solution was S02 pmol of acyl group transferred/min/mg of protein 
where HlyC was estimated as >50% of the total protein. This preparation was used 
routinely for studies of the enzyme. Purified His6-S-tag-HlyC resulted in a preparation of 
similar activity (Table 3).
The size of the active form of HlyC was shown by size exclusion HPLC to be 
-22,500 Mr where fraction 29 showed the highest activty (Figure 7). Thus HlyC was 
enzymatically active as a monomer. The largest Ajgonm peak in Figure 7, fraction 38, 
was DTT in the sample applied. SDS-PAGE of the protein from the fraction which
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Figure 7: Size exclusion HPLC showing Mr of acyl-ACP-proHlyA acyltransferase 
activity. 0.3 mg of S-tag-HlyC in 25 mM HEPES (pH 8.0), 5 mM EGTA, 1 mM DTT, 
0.3 M  urea, extracted from inclusion bodies was applied to a TSK-250 column (Bio-Rad) 
on a Waters model 510 HPLC. Column and elution buffer was 25 mM HEPES (pH 7.2), 
0.05 M  NaCl. Fractions of 0.5 ml were collected, measured for A280 (□) and acyl-ACP- 
proHlyA acyltransferase activity (o). Protein from the peak fraction of enzyme activity 
was analyzed by SDS-PAGE, Figure 5 A lane 5. Arrows denote elution peaks of 
calibration proteins of the indicated sizes in kDa.
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contained the highest acyltransferase activity (Figure 5 A lane S) showed a single protein, 
the size of HlyC.
The reaction rate was linear with respect to HlyC concentration (Figure 8), and 
the amount of product formed was linear with time at 4 °C (Figure 9). Michaelis-Menten 
kinetics were observed. With myristoyl-ACP held constant at 1 pM, proHlyA had a 
Km*w of 0.94±0.1 pM and Vmax*pp 7.5±0.2, and myristoyl-ACP had a Km*pp of 0.48±0.1 
pM, and a Vmu*pp of 6.9±0.5 with proHlyA held constant at 2 pM. Diverse acyl-ACPs 
served as substrates, but when [ l- 14C]palmitoyl-CoA was substituted for radiolabeled 
acyl-ACP, there was no incorporation of radioactivity into proHlyA. The presence of 
urea, up to 3 M, had no effect on the assay. Storage of HlyC in > 0.5 M  urea, however, 
was not tolerated. A variety of cations and anions were examined, and the assay was 
insensitive to ionic strength and ions, with a notable exception. Ca2+ was inhibitory. 
Deleterious effects of Ca2*on proHlyA activation were seen at assay ion concentrations 
above SO pM, and concentrations >200 pM practically halted toxin formation (Figure 
10). The acyltransferase activity was relatively stable. It remained constant indefinitely 
at 4° C or -20° C, but at 25 °C for 16 h about one half of the activity survived. Enzyme 
was destroyed quickly at higher temperatures. Several freeze-thaw transitions were 
tolerated with no diminution of activity.
The pH dependency of the enzyme catalyzed acylation of proHlyA was measured 
over a range of pH at constant ionic strength (Figure 11). Acyltransferase activity was 
undetectable below pH 6.0 and increased sharply between pH 6.5 and 7.5, with maximal 
activity seen at pH 9-10. Activity fell sharply at pH>!0.0. The formation of the
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Figure 8: Dependence of acyl-ACP-proHlyA acyl transfer reaction on HlyC.
Assays were done as described in Materials and Methods in the presence of increasing 
amounts of cell lysate which contained S-tag-HlyC fusion protein.
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Figure 9: HlyC acyltransferase activity as a function of time. Assays were done as 
described in Materials and Methods at various time intervals.
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Figure 10: Effects of Ca2+ on HlyC acyltransferase activity. The assay was earned out as 
described in Materials and Methods except that increasing amounts of Ca2* were added.
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Figure 11: Effects of pH on HlyC acyltransferase activity at constant ionic strength. 
Assays were performed at different pH as described in Materials and Methods.
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radiolabelled product, HlyA, at various pHs was also examined by fluorography of 
redissolved assay precipitates and showed the same trend with pH (data not shown).
Chemical cross-linking of proHlyA, [I4C]acyl-ACP, and HlyC in different 
combinations followed by SDS-PAGE and fluorography resulted in visualization of 
discrete protein-protein complexes (Figure 12). Dimethylsuberimidate (DMS) treatment 
of solutions which contained all three proteins, the complete reaction mixture, resulted in 
the detection of HlyA only, at Mr 107,000, with no evidence of heterotrimer or 
heterodimers at higher molecular weights (lane 6). Exposure of a solution of [ ,4C]acyl- 
ACP and proHlyA to DMS (lane S) did not result in any complexes except those 
generated from [14C]acyl-ACP alone (lane 2). Similar treatment of a solution of 
[l4C]acyl-ACP and HlyC resulted in a complex at Mr -34,500, a heterodimer, (lane 3). 
The Mr -34,500 band was not seen when [I4C]acyl-ACP alone was subjected to chemical 
cross-linking. In addition, a faint, unique band was seen at Mr-23,000 (arrow), the size 
expected for an acyl-HlyC monomer. If  HlyC was denatured by exposure to 5 M  urea 
prior to chemical cross-linking, no heterocomplex or acyl-HlyC were formed (lane 4). 
When a solution of HlyC ar.d [l4C]acyl-ACP was prepared with no exposure to DMS and 
subjected to SDS-PAGE and fluorography, a band at Mr-23,000 was evident (lanes 8 
and 9); the presence of acyl-HlyC-S-tag was confirmed by reaction of the western blotted 
band with S-protein conjugated alkaline phosphatase (data not shown). Furthermore, as 
seen by comparing lanes 8 and 9, the amount of acyl-enzyme increased when the 
concentration of HlyC in the solution was increased. A solution containing HlyC and 
[14C]acyl-ACP was prepared and divided into two parts. Nothing was added to one
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Figure 12: Fluorographic demonstration of acyltransferase reaction proteins which cross- 
linked in the presence of DMS (dimethylsuberimidate) and the formation of an acyl- 
enzyme intermediate (arrow) with and without DMS treatment. Lane I contained 
[14C] labeled mass standards in kDa. Lanes 2 through 6 contained combinations of 
acyltransferase reaction proteins exposed to DMS, subjected to SDS 12% PAGE, and 
fluorograped as described (82). Kodak BioMax MR film was used. Each assay treated 
with DMS contained 2 pM [I4C]myristoyl-ACP plus the following proteins: lane 2, 
none; lane 3,2.5 pM HlyC; lane 4,2.5 pM HlyC that had been exposed to 5 M urea 
overnight and in the reaction; lane 5, 2.3 pM proHlyA; lane 6, 2.5 pM HlyC + 2.3 pM 
proHlyA. Lanes 7 through 10 were assay mixes which were incubated for 10
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Figure 12 (continued): min at 4°C and were not exposed to DMS. Each contained 2 pM 
[uC]myristoyl-ACP plus the following proteins: lane 7, none and lane 8, 10 pM HlyC. 
Lanes 9 and 10 arose from a single 200 pi acyltransferase assay which contained the 
indicated acyl-ACP + 20 pM HlyC; it was divided into two 100 pi aliquots after 
incubation. To one aliquot was added nothing (lane 9) while 10 pM proHlyA was added 
to the other (lane 10); after an additional 10 min incubation at 4 °C, both were processed 
as described in Materials and Methods.
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portion while proHlyA was added to the other. Both solutions were processed like the 
other protein solutions in Figure 12. The portion which had no added proHlyA contained 
acyl intermediate (lane 9). The acyl intermediate disappeared from the other portion 
upon addition of proHlyA and HlyA formation ensued (lane 10).
The demonstration of a reactive covalent acyl-enyzme intermediate indicated that 
the acyltransferase reaction likely proceeded by two partial reactions as follows:
1) acyl-ACP + HlyC <-> [HlyC • acyl-ACP] <-► acyl-HlyC + ACPSH
2) acvl-HlvC + oroHlvA <-> foroHlvA • acvl-HlvCl <-» HlvA + HlvC 
sum) acyl-ACP + proHlyA <-> HlyA + ACPSH
Another means of demonstrating the occurrence of the acyl-enzyme would be to 
show the reversibility of partial reaction 1 . Radioactively labeled ACPSH was made by 
purifying ACPSH from E. coli grown in the presence of [ l - l4C]pantothenate which labels 
the prosthetic group covalently attached to the protein (68,69 ). Unlabeled myristoyl- 
ACP and HlyC were mixed in an assay reaction and incubated for 10  min at 4 °C in order 
to allow formation of unlabeled acyl-HlyC, one of the two substrates in the reverse of 
partial reaction 1. Then radiolabeled ACPSH, the second substrate in the reverse of 
partial reaction 1, was added, and after another 10 min incubation at 4 °C, the proteins 
were precipitated, redissolved, and separated by SDS-PAGE. The formation of 
radiolabeled acyl-ACP from unlabeled acyl-HlyC and radiolabeled ACPSH is shown in 
Figure 13 lanes 6  and 7. Twice as much HlyC was used to generate acyl-HlyC in the 
reaction analyzed in lane 7 compared to that analyzed in lane 6 , and a larger amount of
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myristoyl-ACP was evident on the fluorogram. An assay that contained only acyl-ACP 
and labeled ACPSH (lane 5) showed no labeled acyl-ACP so detectable amounts of 
uncatalyzed acyl group exchange did not occur under the conditions employed. An assay 
that contained only HlyC and labeled ACPSH showed no radioactivity at the position of 
acyl-ACP (not shown). Thus HlyC in the form of acyl-HlyC catalyzed the proposed 
partial reaction 1 in the reverse direction converting ACPSH to acyl-ACP.
Characterization of Diverse Acvl-ACP Substrates Compared with Ervthrocvte Lvsis bv
the Different Acvl-Toxins 
The kinetic parameters of acyl-ACP’s containing different acyl groups were 
determined (Table 4). Proportionality constants, V^/Km  (directly proportional to 
kcai/Km), were used to compare catalytic efficiencies, and myristoyl-ACP was the most 
effective substrate. Its kinetic parameters were used as a reference for comparing those 
of the other substrates, shown as percentages of myristoyl-ACP values in Table 4.
Except lauroyl-ACP, the percentages of myristoyl-ACP Km fluctuated among the various 
acyl-donors while there was not much variation among the Vmu percentages, except for 
palmitoleoyl-ACP. Without the latter acyl-ACP, a double-reciprocal plot of the different 
acyl-ACPs showed unchanging y axis intercepts and increasing slopes, as carbon chain 
length increased (data not shown). This pattern describes a plot of competitive inhibition. 
The two shortest chain length saturated acyl-ACPs were the most effective substrates 
largely because of their low Km values, close to 0.5 pM (Table 4). Increasing chain
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Figure 13: Fluorographic demonstration of the reversibility of partial reaction 1. Protein 
mixtures were prepared, treated, analyzed by 15% SDS-PAGE, and subjected to 
fluorography as described in Experimental Procedures. The following proteins were 
applied to lanes 1-3: lane 1, radioactive mass standards in kDA; lane 2, [I4C]myristoyl- 
ACP, 20 Ci/Mol, 0.5 pg; and lane 3, [14C]myristoyI-ACP, 20 Ci/Mol, 0.25 pg . Reaction 
mixtures of 100 pL containing the indicated proteins prepared and processed as described 
above were analyzed in the following lanes: lane 4, 25 pM [I4C]ACPSH; lane 5, 25 pM 
[I4C]ACPSH + 25 pM myristoyl-ACP; lane 6, 25 pM myristoyl-ACP + 25 pM HlyC 
followed by 25 pM [I4C]ACPSH; lane 7, 25 pM myristoyl-ACP + 50 pM HlyC followed 
by 25 pM [l4C]ACPSH. The [14C]ACPSH was 0.3 Ci/Mol.
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Table 4: KINETIC PARAMETERS OF DIFFERENT ACYL-ACP’S IN  THE 
ACYLTRANSFERASE REACTION*
acyl-ACP acyl chain K
% of 
myristoyl- 
A C P  K n * " ’
v~ mac
% of 
myristoyl- 
ACP
v  *w/v» rrux '  r»m
lauroyl- 12:0 0 46±0.1 96 5.7±0.2 83 12.3
myristoyl- 14:0 0.48±0.1 100 6.9±0.5 100 14.3
palmitoyl- 16:0 0.96±0.1 200 8.5±0.2 124 8.9
palmitolcoyl- 16: l*9 0.91±0.2 190 2.2±0.2 33 2.5
stearoyl- 18:0 8.5±0.5 1771 7.0±0.1 102 0.8
oleoyl- 18: l^9 6.4±0 6 1325 5.9±0.3 87 0.9
*Km*pp is pM, and VRiaxapp is pmol acyl group incorporated/min. The assay procedure and 
computation of kinetic parameters were given under Materials and Methods. Kinetic 
parameters are apparent values for the particular conditions given including the 
concentration of the fixed substrate, proHlyA, which was 2 pM.
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lengths of the saturated fatty acyl-ACPs resulted in increasing Km values, 0.96 jiM  for 
palmitoyl-ACP and 8.5 pM for stearoyl-ACP. The proportionality constants decreased 
with increasing chain length. There was not much difference between oleoyl- and 
stearoyl-ACP’s, but palmitoleoyl-ACP was a much less efficient substrate than 
palmitoyl-ACP. The Km values, however, for each of the two unsaturated fatty acids 
were lower than that of the corresponding saturated homologue, so shortening of the 
carbon chain length perhaps contributed to lowering Km’ s.
The erythrocyte lytic abilities of the different HlyA’s formed by the different 
acyl-ACP donors did not correspond to the amount of acyl group transferred. Thus the 
extent of lysis depended upon the nature of HlyA’s fatty acyl group rather than the 
amount of toxin (Table 5). Acyltransferase assays each contained an identical amount of 
a different acyl-ACP donor, and, following reaction, each had formed different amounts 
of HlyA as predicted by Table 5, column 3. I f  toxicity was independent of the nature of 
the acyl group on the toxin, hemolysis (Table 5, column 5) should parallel toxin 
formation (column 3), which it did not. Although stearoyl-ACP and oleoyl-ACP were 
the least effective acyl group donors, the lesser amounts of toxins produced from them 
were most lytic. The most effective acyl-ACP substrate, myristoyl-ACP, produced 
product, myristoyl-HlyA, that caused half of the lysis that stearoyl-HlyA caused, but 
stearoyl-ACP-supported toxin activation produced 94% less acyl-toxin than did that 
employing myristoyl-ACP. An assay which contained palmitoyl-Co A instead of acyl- 
ACP did not activate toxin; nor did assays which contained only two of the three essential 
components.
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Table 5: COMPARISON OF SUBSTRATE EFFICACIES OF ACYL-ACP’S WITH 
LYTIC ABILITIES OF THE CORRESPONDING ACYL-HLYA’S
acyl-ACP acyl chain
amount of acyl 
group transfer 
(V/Km)*
amount of erythrocyte 
lysis (A«3)b
lysis per unit of acyl 
group transferred0
lauroyl- 12:0 12.3 0.739±0.004 0.6
myristoyl- 14:0 14.3 0.438^0.038 0.3
palmitoyl- 16:0 8.9 0.614±0.012 0.7
palmitoleoyl- 16:1* 2.5 0.451*0.005 1.8
stearoyl- 18:0 0.8 0.785*0.069 9.5
oleoyl- 18:1* 0.9 0.813*0.112 8.7
*The proportionality constant is a measure of the rate of transfer of the respective acyl 
groups to proHlyA. ‘’Lysis of 2% solutions of erythrocytes caused by the addition of 
equal sized aliquots of acyltransferase assays which had been assembled with equal 
concentrations of the respective acyl-ACP’s. Lysis was measured, as described in the 
text, by the A543 1 :1 0  dilutions of the respective erythrocyte lysis assay supernatant 
solutions. ‘The amount of lysis per unit of acyl group transferred was calculated by 
dividing the A$43 (corrected for the 1:10 dilution) of the respective solutions (column 4) 
by the corresponding proportionality constant for the acyltransferase activity of that 
particular acyl-ACP (column 3).
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Steady State Kinetics of HlvC
Since myristoyl-ACP was the most effective substrate for the acyltransferase 
(Table 4), it was used for determination of the steady state kinetic mechanism of HlyC. 
The two-substrate reaction catalyzed by HlyC shown below,
HlyC
proHlyA + acyl-ACP —> HlyA + ACPSH 
likely proceeds by way of one of two possible reaction mechanisms which are 
summarized as follows. One entails formation of a substituted enzyme intermediate 
where one product is released prior to the binding of the second substrate; alternatively, a 
ternary complex is formed where both substrates combine with the enzyme in either a 
random or compulsory order prior to the release of any product. Steady state kinetics was 
done to distinguish between the two general mechanisms. Measurements of initial 
reaction velocities at varying concentrations of one substrate at several fixed 
concentrations of the other substrate yielded data that in double-reciprocal and half- 
reciprocal plots formed patterns that distinguished between a substituted enzyme or 
ternary complex mechanism. Initial reaction rates of proHlyA acylation were determined 
by varying myristoyl-ACP concentrations at different fixed concentrations of proHlyA 
(Figure 14) and by varying proHlyA concentrations at different fixed myristoyl-ACP 
concentrations (Figure 15). In both instances, the graphs showed a series of parallel lines 
on double reciprocal plots (Figures 14A and 15 A) and common intersection of all linear 
plots on the [S]/v axis for half-reciprocal plots (Figures 14B and 15B). Each type of plot
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Figure 14: Myristoyl-ACP initial velocity data at different fixed non-saturating 
concentrations of proHlyA shown as double reciprocal plots (A) and as half-reciprocal 
plots (B).
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Figure 14 (continued): Myristoyl-ACP initial velocity data were obtained at the 
following different fixed concentrations of proHlyA: V, 0.34 pM; □ 1 pM; o, 1.5 pM; 
and X  2 pM. Velocitys (v) were in identical arbitrary units. The inset shows the 
secondary plot graphical determination of the reaction kinetic parameters for proHlyA 
from the respective half-reciprocal plot slopes (1/Vmaxapp) at different [proHlyA] (pM). 
The linear correlation coefficient was 0.96.
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Figure IS: ProHlyA initial velocity data at different fixed non-saturating concentrations 
of myristoyl-ACP shown as double reciprocal plots (A) and as half-reciprocal plots (B).
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Figure 1S (continued): Initial velocity data for proHlyA were obtained at the following 
different fixed concentrations of myristoyl-ACP: o, 0.S pM; □, 0.7S pM; A, 1 pM; and 
V, 2 pM. Velocity (v) was in arbitrary units. The inset shows the secondary plot 
graphical determination of the reaction kinetic parameters for myristoyl-ACP from the 
respective half-reciprocal plot slopes (1/Vmax*pp) at different [myristoyl-ACP] (pM). The 
linear correlation coefficient was 0.96.
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is shown to demonstrate that data describing parallel lines on a double reciprocal plot 
require convergence on the [S]/v axis of a half reciprocal plot (S3). Throughout the 
remainder of this manuscript, kinetic data are displayed as half-reciprocal (Hanes) plots 
which has the best distribution of error throughout the plot (84,85). Each pattern shown 
by the two plotting methods was consistent with a bi bi substituted enzyme (bi bi ping 
pong) kinetic mechanism for HlyC. In contrast, a ternary complex mechanism would 
show a series of plots of differing intercepts on a half reciprocal plot. The kinetic 
constants of the reaction where both substrates are present in saturating amounts were 
determined from secondary plots shown in the insets of Figures 14B and 1SB and also by 
inserting the kinetic parameters obtained from the primary plots (Figures 14 and IS) into 
rate equations (73). There was excellent agreement between the two methods. Kmmyns,oyl' 
ACP was 1.6±0.4 uM, and KmproHlyA was 3 .6±1.2 uM; V™.. was 14.0±1.8 pmoles of acyl 
group transferred/min. The correlation coefficient for the determination of these three 
values was 0.99 for each.
Product Inhibition Kinetics
HlyC acyltransferase activity was not effected by the addition of unlabelled 
palmitoyl-CoA or free fatty acid to the reaction. If, however, ACPSH or HlyA were 
added, the reaction was inhibited. These product inhibitions allowed further 
characterization of the enzyme mechanism. Initial velocity studies of a bi bi reaction can 
place it into two general mechanistic groups, ping pong or sequential, while product 
inhibition studies can provide a finer resolution of the kinetic mechanism. In order to
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define further the kinetic mechanism of HlyC catalysis, the addition of different fixed 
concentrations of each of the products separately to initial reaction velocity studies for 
each substrate was done.
The addition of different fixed amounts of ACPSH to reactions containing 
variable amounts of proHlyA resulted in a family of linear plots, which appeared parallel 
on a double-reciprocal plot (not shown). The parallel lines were verified by plotting the 
data on a half reciprocal plot (Figure 16) where the intercepts converged on the [S]/v axis 
(83). The graphical patterns were consistent with uncompetitive inhibition where both 
and Km*** decreased in response to the presence of increasing fixed amounts of 
product, ACPSH. A similar pattern of inhibition was seen when different fixed amounts 
of ACPSH were added to reactions where myristoyl-ACP was the varied substrate 
(Figure 17). In both cases, Km and Vm, values changed by the same factor as [I] 
increased. Replots of 1/Vmax*,lp, the slopes of Figure 16 and 17, versus [I] were 
hyperbolic for ACPSH product inhibition with respect to both myristoyl-ACP and 
proHlyA (insets). These findings described a kind of mixed-type inhibition in which Km 
and Vmax change by the same factor resulting in parallel line double-reciprocal plots (not 
shown) (86). In contrast to linear uncompetitive inhibition where the curves continue to 
move apart as [I] increases, the displacement between the curves in Figures 16 and 17 
became limiting as [I] increased (double-reciprocal plots not shown). This was shown by 
the hyperbolic replots (insets) and also by plots of initial reaction velocities against [I] at 
fixed [S] which showed a leveling of the velocities at higher [I] values rather than a 
continuous decrement of initial reaction velocities as [I] increased (data not shown).
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Figure 16: ACPSH inhibition with respect to proHlyA. Evaluation of the kinetic 
parameters of proHlyA at a fixed myristoyl-ACP concentration of I pM was done in the 
presence of the following concentrations of the product ACPSH: V, 10 pM; A, S pM; □, 
2.5 pM; and o, 0 pM. Velocity (v) was in identical arbitrary units in all half-reciprocal 
plots. The inset shows the half-reciprocal plot slopes, 1/Vmax*pp, versus the corresponding 
[ACPSH] (pM).
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Figure 17: ACPSH inhibition with respect to myristoyl-ACP. Evaluation of the kinetic 
parameters of myristoyl-ACP was done at a fixed proHlyA concentration of 2 pM in the 
presence of the following concentrations of the product ACPSH: V, 20 pM; A, 5 pM; □, 
2.5 pM; and o, 0 pM. Velocity (v) was in identical arbitrary units in all half-reciprocal 
plots. The inset shows the half-reciprocal plot slopes, 1/Vm«*pp, versus the corresponding 
[ACPSH] (pM).
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Thus ACPSH inhibition with respect to both myristoyl-ACP and proHlyA at fixed, 
unsaturating values of each other was mixed-type inhibition.
Prior to studying the effects of the product, HlyA, on reaction rates, any potential 
for additional acylation of HlyA was examined. Purified HlyA produced in vivo was 
obtained from E. coli containing pEKSO, a plasmid encoding for the hemolysin operon. 
The in vivo produced toxin was subjected to possible acylation in the assay milieu, which 
contained radiolabeled myristoyl-ACP and HlyC. HlyA so treated was not acylated. It 
was not visualized on fluorography after extended exposure nor was it radioactive when 
isolated and measured in a liquid scintillation counter.
Upon addition of different fixed amounts of the product HlyA to reactions 
containing variable amounts of myristoyl-ACP, the resulting primary double-reciprocal 
plots all intersected at the same point on the 1/v axis (not shown). In confirmation of this 
pattern, the half-reciprocal primary plots (Figure 18) showed a series of parallel lines. 
These findings were diagnostic of competitive inhibition. The primary plots will not 
distinguish among the following types of competitive inhibition: one-site, pure 
competitive inhibition; two-site, pure competitive inhibition, and partial competitive 
inhibition (87). The three types of competitive inhibition can be distinguished by plotting 
reaction velocity versus [I] at a fixed substrate concentration. In partial competitive 
inhibition, the resulting curve reaches a plateau at a limiting velocity, and the reaction 
rate shows no tendency to approach zero. In contrast, both one-site and two-site types of 
pure competitive inhibition will give plots that indicate that reaction velocity approaches
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Figure 18: HlyA inhibition with respect to myristoyl-ACP. Evaluation of the kinetic 
parameters of myristoyl-ACP was done at a fixed proHlyA concentration of 2 uM in the 
presence of the following concentrations of the product HlyA: V, 2.3 |iM; A, 1.5 |iM; □, 
0.3 pM; and o, 0 pM. Velocity (v) was in identical arbitrary units in all half-reciprocal 
plots. The inset shows the double reciprocal plot slopes, Km*pf>/Vmax*pp, versus the 
corresponding [HlyA] (pM).
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zero upon sufficiently increasing [I]. Such a plot of the data from Figure 18 showed no 
leveling off of the reaction velocity as [I] increased so the inhibition was not partial 
competitive inhibition (Figure 20A). Furthermore, as shown in the inset in Figure 18, the 
replot of double reciprocal plot slopes versus [I] was parabolic; this is diagnostic of two 
site, competitive inhibition (87). Similar plots of data describing one-site pure 
competitive or partial competitive systems would, in comparison, yield linear and 
hyperbolic replots, respectively. Dixon plots (reciprocal velocity values at fixed [S] 
against [I]) and plots of Kmapp versus [1] were both parabolic (not shown) as would be 
expected in two-site, pure competitive inhibition (87).
When different fixed amounts of the product HlyA were added to reactions where 
proHlyA concentration was varied, a primary plot pattern like that described above for 
HlyA inhibition with respect to myristoyl-ACP was observed. HlyA inhibited with 
respect to proHlyA as shown in Figure 19 where the primary half-reciprocal plots at 
different HlyA concentrations formed parallel lines. The corresponding double- 
reciprocal plots showed increasing slopes with increasing inhibitor concentration while 
all plots intersected on the 1/v axis (not shown). These patterns indicated competitive 
inhibition. As mentioned above, there are several types of competitive inhibition, and all 
have the same primary plot pattern. A secondary plot of initial velocity versus [HlyA] at 
fixed [S] showed a tendency for the velocity to plateau at higher concentrations of HlyA 
as shown in Figure 20B. This was in contrast to the results from above shown in Figure 
20A where a continuously decreasing velocity was observed as inhibitor concentration 
increased. This finding indicated partial competitive inhibition. In confirmation of
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Figure 19: HlyA inhibition with respect to proHlyA. Evaluation of the kinetic 
parameters of proHlyA was done at a fixed myristoyl-ACP concentration of 1 pM in the 
presence of the following concentrations of the product HlyA: V, 2.7 pM; A, 1.3 pM; □, 
0.6; and o, 0.06S pM. Velocity (v) was in identical arbitrary units in all half-reciprocal 
plots. The inset shows the double reciprocal plot slopes, Km*p,7Vmaxapp, versus the 
corresponding [HlyA] (pM).
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Figure 20: Plots of initial velocities at fixed [S] in the presence of product, [HlyA] (pM) 
with myristoyl-ACP (A) or proHlyA (B) as the variable substrates. Initial reaction 
velocities are given in dpm. In (A), in the presence of different concentrations of HlyA 
(pM), reaction velocities were determined at the following different [myristoyl-ACP]: A, 
3 pM; □, I pM; and o, 0.5 pM. [ProHlyA] was fixed at 2 pM. In (B), in the presence of 
different concentrations of HlyA (pM)> reaction velocities were determined at the 
following different [proHlyA]: o, 3 pM; □, 2 pM; and A, 1 pM. [Myristoyl-ACP] was 
fixed at 1 pM.
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partial competitive inhibition (also called hyperbolic inhibition), the replot of double 
reciprocal plot slopes versus [HlyA] was hyperbolic (Figure 19 inset) (88). Unlike the 
situation with simple linear inhibition, Kj cannot be obtained from the intercept of the 
replot, but the equation for partial competitive inhibition can be converted into a linear 
relationship (89). In this way, a Kj of 4.3 pM HlyA was obtained from a linear plot 
(Figure 21) of 1/A slope against l/[HlyA].
The partial competitive inhibition seen when [HlyA] was varied with respect to 
proHlyA may be regarded as a variant of mixed-type inhibition (90); the basis for this 
will be discussed later. The product inhibitions for the HlyC catalyzed reaction are 
summarized in Table 7. At fixed, nonsaturating concentrations of proHlyA or myristoyl- 
ACP respectively, ACPSH inhibitions with respect to myristoyl-ACP or proHlyA were 
each mixed-type inhibition. HlyA inhibition with respect to myristoyl-ACP, at fixed, 
nonsaturating concentrations of proHlyA, gave a pattern of competitive inhibition. A 
different pattern was obtained for HlyA inhibition with respect to proHlyA at fixed 
nonsaturating concentration of myristoyl-ACP; a pattern consistent with a form of mixed- 
type inhibition was observed. The product inhibition patterns of the acyltransferase 
reaction shown in Table 6 conformed to an uni uni iso uni uni ping pong kinetic 
mechanism with isomerization of the F form of the enzyme (91).
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Figure 21: Determination of the Kj for HlyA inhibition with respect to proHlyA at fixed 
[myristoyl-ACP]. The relationship between Km*pp/V1IUX*pp (double-reciprocal plot slopes 
or half-reciprocal plot intercepts) and different [HlyA] provides -Ki on the x intercept 
when the relationship is linear (S9). Data are from Fig. 19. The linear correlation 
coefficient was I.
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Table 6: PRODUCT INHIBITION PATTERNS*
73
variable substrate product fixed substrateb inhibition pattern6
myristoyl-ACP ACPSH proHlyA mixed-type
proHlyA ACPSH myristoyl-ACP mixed-type
myristoyl-ACP HlyA proHlyA competitive
proHlyA HlyA myristoyl-ACP mixed-type
*The assay procedure and reaction conditions are given in Experimental 
Procedures. bNonsaturating concentrations of fixed substrates were used, inhibition 
pattern notations are those described by Segel (91).
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Chemical Mechanism of HlvC
Chemical Modification of HlvC
As discussed earlier, HlyC appears to be a unique acyltransferase resembling no 
other known acyltransferases. However, it has been demonstrated that some RTX C 
proteins can acylate pro-RTX toxins from different organisms, indicating a similar mode 
of action for the various RTX C acyltransferases. To elucidate the chemical mechanism 
of this unique enzyme, the deduced amino acid sequences of 13 different RTX C proteins 
were compared. The sequence alignment shown in Figure 22 reveals a high degree of 
identity, with the majority of homology concentrated in the N-terminal region. Possibly, 
the N-terminal region of HlyC may be involved in the acyl transfer reaction; whereas, the 
unique C-terminal regions of the various acyltransferases may be involved in recognition 
of the diverse protoxins. Out of 170 residues in HlyC, 37 are totally conserved in the 13 
RTX C gene products (Figure 22). Of particular interest to us were those residues that 
could covalently bear an acyl group since HlyC forms an acyl-enzyme intermediate in the 
presence of its first bound substrate, acyl-ACP. To investigate the chemical mechanism 
for the acyl transfer reaction, HlyC was covalently modified by a number of chemical 
reagents. The reactions for the various chemical modification reagents used in this study 
are shown in Figure 23.
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HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
RT1C_ACTPL
RT2 C_ACTPL
RT3C_ACTPL
HLYC_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PASSP
CYAC
HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
RT1C_ACTPL
RT2C_ACTPL
RT3C_ACTPL
HLYC_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PAS S P
CYAC
30
PLBRNlPVSL
plI rnI pv sl
plI rnI pv sl
plbckI p l s v
plI rkJ p l s l
pmI rnI sv sl
plI keI s i s l
plI rnI s l s l
slI keI sc el
slI keI sckl
plI keI sc e l
plI reI sc el
pmI rdI pvhl
NLSLEN 
NLSLEN 
NLSLEN 
SLDLEC VK| 
NLNLEN 
KLTLES 
NLTLTN VK
n l s l e nT
DLNLET|VK 
DLNLET VK 
DLNLEN VK 
DLSLET VK 
LMDADT LS
VLPA
VLPA
VLPA
VLPA
LMK VIPA
VI PA
LAC VIPA
VIPA 
VIPA 
TLAF
INDV
LDDV.
VMAPS
Figure 22: Partial amino acid sequence alignment of 13 RTX toxin C gene products. 
HLYC_ECOLI, £. coli HlyC, pHlyl52 encoded, acession no. p06736; HLCl_ECOLI, E. 
coli strain J96 HlyC, chromosome encoded, accession no. p09984; HLC2_ECOLI, E. coli 
strain 2001 HlyC, chromosome encoded, accesion no. p09985; HLYCEH, E. coli
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
76
HLYC_ECOLI D I.
HLC1_EC0LI V I
HLC2_EC0LI D I
HLYCEH D I
RT1C_ACTPL D I
RT2C_ACTPL D I
RT3C_ACTPL D I
HLY C_ACTAC D I
HLC1_PASHA D
HLC3_PASHA D
HLCB_PASHA D
HLYC_PAS S P D
CYAC D I
- -GA
--ME
HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
RT1C_ACTPL
RT2C_ACTPL
RT 3 C_ACTPL
HLYC_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PASSP
CYAC
GKVSEFH 
GKVSEFH 
GKVSEFH 
GKIAEFH 
GKISEFH 
GKIIYLK 
AKIIHVQ GQ
137
GK
GK
GK
GG
GK
GK
GKITEFH
GKIAYFK
GKITYFK
GKISYFK
GKIAYFK
ARVKEYR RA
GK
GK
GK
GK
GN
108 
YKYMR 
YKYMR 
YKYMR 
YKYMR 
YKHMR 
YKHMR 
-NTBYRYMR 
--YV^YKHMR 
YKKMC 
YKKMC 
YKKMC 
IKNVS
dn raBr r a l a
147
IDKQLANKIF
IDKQLANKIF
IDKHLANKIF
IDKKLASKIF
IDKKLASKIF
ITKKVAEKTF
INKFTAKKLI
VDKQLANKIF
LDKKTAKKRF
LDKKTAKERF
LDKKTAKKRF
LDKKTAKKRF
LDAAATRAQL
118
KKFBDELFRA 
KKF DELFRA 
KKF DELFLA 
KKY YELFRP 
DNF NELFRA 
QRF YDIGRA 
KKF NEVFRA 
KSF YDLFRS 
QKY DMIVRS 
QKY DMIVRA 
QKY DMIVRS 
E-I DYSRQI 
ERH DSVGRS
KQ
KQ
KQ
RQ
QQ
LQ
QQ
DI
HHE
HHE
HHE
HHE MSE 
HFE MSE
EQE
QQ QEE
HFE
DT QEE
QEE
DT QEE 
DT QER 
DR HAE
127
IRVDPKTH-V
IRVDPKTH-V
IRVDPKTH-V
IRLDESSK-T
IRVDPDSR-V
IRIYPSKKDT
IRVYPGST-E
IRVYKGSS-E
IRFYPKQKEL
IRFYPKQKEL
IRFQPNQKSV
YTLLSKTKRT
LRVRRGGDT-
157
ITE
ITE
ITE
ITA
IQV
INE
ATA
ATA
ATA
GAA
IAG
Figure 22 (continued): 0157:H7 strain EDL 933 HlyC, plasmid encoded, translation of 
nucleotide sequence accesion no. x8089l; RTIC ACTPL, A. pleuropnenmoniae Apx- 
IC, accesion no. p55132; RT2C_ACTPL, A. pleuropneumoniae Apx-IIC, accesion no. 
p i5376; RT3C_ACTPL, A. pleuropneumoniae, Apx-IIIC, accession no. q04474; 
HLYC_ACTAC, A. actinomycetemcomitans LktC, accession no. p 16461;
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Figure 22 (continued): HLC I P  ASH A, P. haemolytica serotype A1 LktC, accession no. 
pl6533; HLC3_PASHA, P. haemolytica sertoype T3 LktC, accession no. p55120; 
HLCB_PASHA, P. haemolytica serotype A11 LktC, accession no. pSS121; 
HLYC_PASSP, P. haemolytica-Wke sp. LktC, accession no. p55124; CYAC, B. pertussis 
CyaC, translation of nucleotide sequence accession no. mS7286. Nonconserved amino 
acids are shown in uppercase letters; conserved residues are shown in bold uppercase 
letters. Amino acid residues that are identical in all 13 RTX C proteins are shaded. The 
sequence aligment was done using the Hibio Prosis protein analysis software by Hitachi. 
Amino acid sequence number refers to positions in the E. coli HlyC encoded by plasmid 
pHlyl52.
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Figure 23: Chemical reactions for different chemical modifiers with their target residues 
(77).
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The RTX acyltransferases all contain a single conserved Cys residue, Cys 58 in 
HlyC. NEM, which reacts specifically with sulfhydryl groups (78), did not affect enzyme 
activity (Table 7). Since the nature of the environment surrounding the reactive group 
can effect its reactivity with various chemical reagents, a second more hydrophobic 
sulfhydryl-specific modifying reagent, PCMB (92), was also tested as an inhibitor for the 
acyltransferase. Again, there was no decrease in enzyme activity (Table 7), suggesting 
a -SH group is not necessary for catalysis. HlyC was also insensitive to PMSF or 
AEBSF (Table 7), which could potentially modify one or more of the three conserved 
serines; residues 20, 58, and 76, suggesting that the enzyme is not a serine-dependent 
acyltransferase.
HlyC contains one conserved His at position 23, which could be involved in the 
enzymatic transfer of an acyl chain. His could function as a base deprotonating a 
nucleophilic residue accepting the acyl chain or possibly serve as the acyl acceptor, 
although an acyl-imidazole enzyme intermediate has never been reported previously. 
HlyC was rapidly inactivated by DEPC at pH 6.0 (Table 7 and Figure 24). At this pH, 
the reagent is highly specific for histidine residues producing N-carbethoxyhistidine 
(Figure 23 reaction 4), while at pH 8.0 the reagent may modify cysteine, tyrosine, and 
lysine residues (79). HlyC treated with 1 mM DEPC at pH 6.0 retained 16±1% 
acyltransferase activity as compared to 68±0% remaining activity at pH 8.0 suggesting a 
specificity for histidine (Table 7).
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Table 7: INHIBITION OF HLYC ACYLTRANSFERASE ACTIVITY BY
CHEMICAL MODIFIERS
Modifier [Modifier]
(mM)
Reaction Conditions* % Activity 
Remaining1*
NEM 1.0 0.1 M KP04 (pH 7.0), 15 min 100±10
PCMB 1.0 20 mM Mes (pH 6.0), 10 min 117±1
PMSF 1.0 25 mM Hepes (pH 8.0), 10 min 95±10
AEBSF 1.0 25 mM Hepes (pH 8.0), 10 min 126±0
DEPC 1.0 0.1 M KPO4 (pH 6.0), 10 min 16±1
DEPC 1.0 0.1 M KPO4 (pH 8.0), 10 min 68±0
TNM 1.5 0.05 M Tris (pH 6.0), 30 min 81±1
TNM 1.5 0.05 M Tris (pH 8.0), 30 min 20±1
NAI 1.3 50 mM Hepes (pH 7.5), 30 min 83±2
PG 5.0 25 mM Hepes (pH 8.0), 1 h 10±2
aAll chemical modification reactions were performed at 25 °C. bActivity is the % of the 
control reaction without modifier. As described in the Materials and Methods a separate 
control was completed for each modification reaction. On average, control reactions 
containing 10 gg of HlyC gave 35.0±2.5 pmoles o f acyl group transferred/assay.
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Figure 24: Inhibition of HlyC acyltransferase activity by protein modification reagents. 
HlyC was incubated with increasing concentration of (□) DEPC, (o) TNM, or (A) PG. 
Chemical modification reactions were performed as described in the Materials and 
Methods with each reaction having its own control not exposed to the chemical modifier. 
Control activities for the DEPC, TNM, and PG modification experiments were 29.0±3.0, 
40.0±1.0, and 37.0±1.0 pmoles acyl group transferred/assay, respectively. Assays 
contained 10 pg HlyC.
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Treatment of DEPC modified HlyC with 100 mM NH2OH (pH 7.0) (Figure 25) 
resulted in a time dependent re-activation of the enzyme activity with 87±1% 
acyltransferase activity after 4 h, indicating that inactivation was not due to lysine, 
tyrosine, or sulfhydryl modification (79). DEPC modification of cysteine or lysine 
residues is not reversed by NH2OH treatment and modified tyrosines are reversed at a 
much slower rate (79). Incomplete reactivation of the enyzme could be attributed to 
either modification of lysyl residues which are not affected by hydroxylamine treatment; 
but are essential for HlyC function, or possibly due to the formation of a disubstituted 
histidyl derivative that is not regenerated by hydroxylamine (79). Modification of 
hisitidine by DEPC was confirmed by difference spectroscopy of DEPC modified and 
native HlyC, showing an absorption maximum o f242 nm characteristic for N- 
carbethoxyhistidine with no significant decrease in abosrbance at 278 nm characteristic 
of ethoxyformylation of tyrosine (Figure 26) (79). The inactivation of the acyltransferase 
by DEPC followed pseudo first-order kinetics and correlated with the formation of N- 
carbeothoxyhistidine as shown by increasing absorbance at 242 nm over time (Figure 
27).
HlyC contains two conserved tyrosines, Tyr 70 and Tyr 150, that could serve as 
acyl acceptors forming oxygen esters. At pH 8.0, TNM can specifically modify tyrosine 
residues producing 3-nitrotyrosine (Figure 23 reaction 5); whereas, at a pH 6.0 the 
reagent oxidizes sulfhydryl groups (93, 94, 95). HlyC was inactivated by TNM at pH 8.0 
(Table 7 and Figure 24) with only 20±1% activity remaining at pH 8.0 as compared to
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Figure 25: Reversibility of DEPC modification of HlyC. HlyC was incubated with 2 mM 
DEPC for 10 min at 25 °C until 13% acyltransferase activity remained followed by 
addition of NH2OH (pH 7.0) to a concentration of 100 mM. At various time points, 
aliquots containing 10 pg of HlyC were removed and acyltransferase activity measured. 
Activity was expressed as the percentage of a control reaction not exposed to DEPC but 
incubated with 100 mM NH2OH (pH 7.0) for 4 hrs. Control HlyC (10 pg) activity was 
50.0±1.0 pmoles acyl group transferred/assay.
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Figure 26: UV absorbance difference spectra demonstrating the effect of DEPC 
modification of HlyC. A 1.0 mg/mL S-tag-HlyC solution in a double sectored cuvette 
was modified with 1 mM DEPC in 0.1 M  KPO4 (pH 6.0) at 25 ?C as described in 
Materials and Methods. Spectra were recorded at 1,2,4,6,10, 15, and 20 min intervals. 
The difference spectrum exhibits an absorbance peak at 242 nm that increases over time.
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Figure 27: Correlation between the rate of DEPC modification (□) and loss of HlyC 
acyltransferase actvity (o). S-tag-FflyC in 0.1 M  KPO4 (pH 6.0) was treated with 1 mM 
DEPC at 25 °C and at various time intervals 10 pg aliquots of HlyC were removed and 
assayed for activity (o). Activity is expressed as the percentage of a control reaction 
(38.0±2.0 pmoles acyl group transferred/assay) containing 10 pg HlyC that was not 
exposed to DEPC. For absorbance studies, S-tag-HlyC modified under the same 
conditions was monitored for change in the absorbance at 242 nm.
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81±1% activity remaining at pH 6.0 indicating that inactivation by TNM is not due to 
thiol oxidation. Modification of tryptophan residues was not considered likely since this 
reaction takes place at pH 9.0 or greater (96, 97). Comparison of the modified and 
unmodified HlyC spectra showed an absoprtion maximum at 428 nm (Figure 28), 
consistent with the formation of nitrated tyrosine (94). TNM inactivation followed 
pseudo first-order kinetics and this decrease correlated with the formation of 3- 
nitrotyrosine as shown by the increase in absorbance at 428 nm over time (Figure 29).
TNM may induce the precipitation of some proteins through protein crosslinking 
resulting in loss of enzyme activity that is unrelated to tyrosine nitration (98, 99).
Possible cross linking of HlyC was tested by treating the enzyme with TNM followed by 
SDS-PAGE and western blotting using the S-protein alkaline phosphatase conjugate. 
There was no evidence of dimer, trimer, or large aggregate formation indicating that 
inactivation of HlyC was not due to protein cross linking (data not shown).
Like TNM, N-acetylimidazole under mild conditions reacts specifically with 
tyrosyl groups of proteins (100). Unlike TNM, the reaction directly effects the -OH  
group of the residue forming O-acetyltyrosine (Figure 23 reaction 6). HlyC activity was 
not affected by modification with N-acetylimidazole; 83±2% of acyltransferase activity 
remained after treatment with 1.3 mM of the reagent (Table 7). Acetylation of tyrosyl 
residues within HlyC was confirmed by a decrease in the absorbance at 278 nm (data not 
shown). The small decrease in activity probably stems from modification of lysyl 
residues (100). Acetylation of tyrosine residues had no effect on acyltransferase activity 
but, nitration of tyrosines almost completely inactivated the enzyme, suggesting that a
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Figure 28: UV-Vis Spectra of TNM modified (-----) and unmodified (—) HlyC. An 2.72
mg/mL S-tag-HlyC solution in 0.05 M  Tris pH 8.0 was modified with a 50-fold molar 
excess of TNM (6.0 mM) for 30 minutes at 25 °C in a double sectored cuvette as 
described in Materials and Methods.
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Figure 29: Correlation between the rate of TNM modification (□) and loss of HlyC 
acyltransferase actvity (o). S-tag-HlyC in 0.05 M Tris (pH 8.0) was treated with 1 mM 
TNM at 25 °C and at various time intervals 10 pg aliquots of HlyC were removed and 
assayed for activity (o). Activity is expressed as the percentage of a control reaction 
containing 10 pg of HlyC (45.0±0 pmoles acyl group transferred/min) that was not 
exposed to TNM. For absorbance studies, S-tag-HlyC modified under the same 
conditions was monitored for change in the absorbance at 428 nm.
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tyrosine residue is important, but its functional -OH group is not.
Phenylglyoxal (PG) is relatively specific for arginine at neutrality giving 
derivatives containing two PG moieties per guanidino group (Figure 23 reaction 7) {101, 
102). Since HlyC contains two conserved arginines, residues 24 and 87, (Figure 22) the 
effects of PG on enzyme activity was tested. HlyC was sensitive to increasing 
concentrations of the reagent (Figure 24) with only 10±2 % of the control activity 
remaining following treatment with S mM PG, implicating an essential arginine residue.
The presence of substrate during chemical modification can be used to selectively 
prevent modification of residues that are somehow protected upon substrate binding.
This protection is usually explained as the residue being located within the active site; 
however, protection may occur as a result of structural changes following substrate 
binding leading to a change in the accessibility of the residue to the chemical modifier 
{103). Protection against TNM*, DEPC-, and PG-induced inactivation of HlyC was 
examined using acyl-ACP and ACPSH. Acyl-ACP consistently offered significant 
protection from the various chemical modifiers, whereas ACPSH was unable to protect 
HlyC from TNM and DEPC modification, and offered little protection from PG (Figure 
30).
Characterization of HlvC Mutants
Chemical modification of HlyC provided information for possible residues 
essential for the catalytic mechanism of the enzyme. In order, to examine the function of 
specific conserved residues and possibly corroborate the chemical findings, site-directed
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Figure 30: Protection of HlyC activity against DEPC, TNM, or PG inactivation by either 
acyl-ACP or ACPSH. Enzyme was modified with either 2 mM DEPC, 50-fold molar 
excess (0.22 mM) of TNM, or 5 mM PG. Prior to the addition of the chemical modifier, 
-  2 pM HlyC was incubated with either 2 pM unlabeled myristoyl-ACP or ACPSH. 
After modification, the unlabeled ACPs were removed by 70% (NH4>2S0 4  precipitation 
at pH 7.0 and the enzyme assayed using [I4C]myristoyl-ACP as described in Materials 
and Methods.
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mutagenesis studies of the acyltransferase were employed. Residues that were 
conserved within the 13 different RTX toxin acyltransferases (Figure 22) were 
individually mutagenized, the mutation confirmed by DNA sequencing (data not shown), 
and the corresponding HlyC expressed and purified as a His6-S-tag fusion protein. The 
expression of all HlyC mutants (data not shown) was identical to native HlyC (Figure 3). 
The acyltransferase activity was examined for mutant HlyCs isolated from inclusion 
bodies in HED 6 M  urea followed by slow renaturation of the enzyme by dialysis 
(refolded HlyC) or for HlyC in which the urea concentration was lowered by dilution 
with HED buffer (quickly diluted HlyC). The initial activity studies for refolded and 
quickly diluted HlyCs are summarized in Table 8. Activites ranging from 0-10% of the 
native activity were indiscernible from 0 using the HlyC assay system presented, a 
common problem in assessing activities of mutant proteins {104).
Mutation of the conserved and only cysteine (Cys 57) of HlyC to an alanine 
showed the same level of acyltransferase activity as did wild-type enzyme. Changing 
conserved serines 58 and 76 of HlyC to alanines, showed little o r  no decrease in activity; 
however, the S20A mutant retained only -30% wild-type activity. Interestingly, the 
S76A mutant experienced ~30% increase in activity resulting in native acyltransferase 
activity upon slow renaturation of the enzyme as compared to the quick diluted HlyC. 
Obviously, Ser 20 and 76 have some part in wild-type acyltransferase function.
HlyC was very sensitive to DEPC and TNM, leading to acetylation of histidine 
residues and nitration of tyrosine residues respectively. Mutation of the conserved
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Table 8: ACYLTRANSFERASE ACTIVITES OF SINGLE-SITE MUTANT HLYCS
Mutation
% of Wild-Type Acyltransferase Activity*
Quick Diluted HlyC Refolded HlyC
G11A 14.1*0.1 23.2*0.4
G85A 0.0*0.4 3.6*04
H23A 7.9±0.3 4.4*0.1
H23S 6.6±0.4 5.6*04
H23C 11.7*1.5 3.5*09
R24A 66.7*1.8 63.8*0.2
R87A 17.7*0.6 86.1*1.7
S20A 36.3*0.3 31.2*0.3
S58A 78.1*0.4 75.3*1.3
S76A 63.2*7.3 94.1*4.0
E67A 75.6*0.3 107.0*2.1
D86A 64.3±0.1 70.4*0.2
Y70G 10.0±1.1 11.8*0.1
Y70F 74.5±5.2 104.0*2.5
Y150G 21.1*1.2 44.3*0.7
Y150F 91.6*1.7 85.5*4.3
C57A 90.0*0.7 95.6*2.5
'Acyltransferase activities were measured as described in Materials and Methods. Slowly 
refolded wild-type HlyC activity was 71.0*2.3 picomoles acyl group transferred /5 pg 
enzyme. Wild-type quick dilution HlyC activity was 47.0*2.4 picomoles acyl group 
transferred/5 pg enzyme. Each % is the average of at least 3 determinations enzyme *  
standard deviation.
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histidine and the two conserved tyrosines significantly effected acyltransferase activity. 
Changing conserved His 23 to an alanine led to total inactivation of the acyltransferase. 
Mutation of conserved Tyr 70 and Tyr ISO to glycines resulted in inactivation of the 
acyltransferase for the Y70G mutant and 40% of the wild-type activity for the refolded 
Y1S0G mutant. Like the S76A mutant, the Y1S0G HlyC showed a difference in 
acyltransferase activity between the quickly diluted and refolded enzyme with a 20% 
increase upon slowly refolding the protein.
Mutation of conserved arginine residues 24 and 87 to alanines affected HlyC 
activity. The R24 A HlyC mutant possessed ~65% of the wild-type activity for both the 
quickly diluted and refolded HlyCs; whereas, the R87A mutant demonstrated a 
significant difference between the two methods of renaturing HlyC. Quickly diluted 
R87A HlyC retained only ~20% of the wild-type activity, but upon slowly refolding it 
functioned at wild-type levels with ~90% activity. Becuase both R24A and R87A HlyCs 
possessed significant acyltransferase activities upon refolding, these mutants were tested 
for sensitivity to PG. Both HlyCs were still inhibited by PG to the same extent as the 
inhibition seen with the wild-type enzyme (data not shown), suggesting that both Arg 87 
and Arg 24 could be the potential targets for PG modification as well as other arginines 
within HlyC.
No chemical modifications of HlyC were done that would modify acidic residues, 
but two mutants were made changing two conserved acidic residues to alanines.
Changing Glu 67 to an alanine had no effect on enzyme activity. Changing Asp 86 to an 
alanine resulted in a 30-40% decrease in acyltransferase activity. These data suggest that 
neither residue is critical for HlyC activity, but Asp 86 does seem necessary for wild-type
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acyltransferase function. Mutation of the two conserved glycines, Gly 11 and 85, to 
alanines were detrimental to acyltransferase activity resulting in 14-20% activity for 
mutant G11A and no activity for the G85A mutant.
To examine further the function of residues His 23, Tyr 70, and Tyr 150 these 
residues were mutated. Tyrosines 70 and 150 were mutated to phenylalanine. These 
HlyCs, Y70F and Y150F, functioned at native levels. Furthermore, both mutants were 
inactivated like the native enzyme by TNM (data not shown) therefore both Tyr 70 and 
150 are potential targets for TNM along with other tyrosines in the enzyme. His 23 was 
also mutated to a serine and a cysteine residue, both of which could bear an acyl group. 
Like the H23A mutant, the H23S and H23C mutant acyltransferases showed no activity.
Mutant HlyCs were monitored for the formation of [ t4C]acyl-enzyme 
intermediate and products resulting from chemcial cross-linking reactions with [14C] 
myristoyl-ACP. The data are summarized in Figure 31, Figure 32, and Table 9. 
Essentially, any mutant HlyC that was able to function at or near wild-type levels 
produced [14C]acyl-enzyme intermediate and cross-linked with [l4C]myristoyl-ACP like 
the native enzyme (Refer to Figure 12). Mutant HlyCs functioning in this manner 
included the following: R24A, C57A, S58A, E67A, Y70F, S76A, D86A, R87A, and 
Y150F. In some cases, single-site mutations of HlyC produced acyltransferases able to 
cross-link to acyl-ACP, but unable to produce acyl-HlyC intermediate. These mutations 
include H23A, H23C, H23S, S20A, G11 A, Y70G, and Y150G. H23A, H23S, H23C, and 
S20A HlyCs all cross-linked at normal levels, while the G11 A, Y70G, and Y150G 
mutants cross-linked at much lower levels as compared to the wild-type control. Only 
the G85A mutant resulted in a loss of heterodimer and acyl-intermediate formation. No
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Acyl-HlyC Dimer
[wClacyl-ACP
|£g§aAcyl-HlyC Dimer
|wC|acyl-ACP
l,4Clacyl-ACP
Figure 31: Fluorographic demonstration of [l4C]acyl-HlyC enzyme intermediate 
formation for mutant HlyCs. All reactions contained 2.5 pM [uC]myristoyl-ACP
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Figure 31 (continued): A reaction containing only [MC]myristoyl-ACP is shown in the 
top fluorograph (negative control). When present in reaction, the particular HlyC is 
given above its respective lane. Reactions contained SO pM of enzyme. Each 
fluorograph respresents a separate experiment and contains its own native control to 
which the mutant HlyCs were compared. Reactions were carried out as described in 
Materials and Methods.
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Heterodimer
[wC|acyl-ACP
Heterodimer
|MC|acyl-ACP
lMClacyl-ACP
Figure 32: Fluorographic demonstration of Acyl-ACP-HlyC heterodimer formation upon 
chemical cross-linking with [I4C]myristoyl-ACP and mutant HlyCs in the presence of 
DMS
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Figure 32 (continued): All reactions contained 2 pM [l4C]myristoyl-ACP and DMS.
A reaction with 2 pM [,4C]myristoyl-ACP alone in the presence of DMS (negative 
control) is shown in the top fluorograph. When present in reaction, the particular HlyC is 
given above its respective lane. Reactions contained 10 pg (4.S pM) of enzyme. Each 
fluorograph represents a separate experiment and contains its own native control to which 
the mutant HlyCs were compared. Reactions were carried out as described in Materials 
and Methods.
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Table 9: SUMMARY OF ACYL-ENZYME INTERMEDIATE AND ACYL-ACP- 
HLYC HETERODIMER FORMATION OF HLYC MUTANTS'
Mutation Acyl-Enzyme Formation Acyl-ACP-HlyC 
Heterodimer Formation
G11A Not Detectable Low
G85A Not Detectable Not Detectable
H23A Not Detectable Normal
H23S Not Detectable Normal
H23C Not Detectable Normal
R24A Intermediate Intermediate
R87A Low Normal
S20A Not Detectable Normal
S58A Normal Normal
S76A Normal Normal
E67A Normal Normal
D86A Intermediate Intermediate
Y70G Not Detectable Low
Y70F Normal Normal
Y150G Not Detectable Low
Y150F Normal Normal
C57A Normal Normal
'Fluorographs from Figure 31 and 32 were scanned followed by densitometry 
measurements using the UnScan It Software. Densities of bands produced by mutant 
HlyCs were compared to bands produced by the native HlyC control on each fluorograph. 
Intensities o f the bands were ranked as either normal, intermediate, low, or not 
detectable.
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mutation produced an enzyme capable of acyl intermediate formation production with the 
lack of heterodimer production. For mutations S58A, S76A, R24A, E67A, Y70F, and 
Y1S0F an additional band was seen in acyl-enzyme formation experiments at the size 
expected for an acyl-HlyC dimer (Figure 31), whereas, wild-type enzyme never produced 
acyl-enyzme in the dimer form in any of the fluorographs.
The kinetic parameters for myristoyl-ACP and proHlyA were determined for 
His6-S-tag-HlyC and mutant fusion proteins with detectable acyltransferase activity. 
Myristoyl-ACP had a Km^of 0.61±0.1 pM, and a Vnux*P!> of 14.0±0.5 pmoles of acyl 
group transferred/min with proHlyA held constant at 2 pM (Table 10). ProHlyA had a 
Km*pp of 2.19±0.17 pM and a Vm«*pp of 15.2±2.7 pmoles acyl group transferred/min with 
myristoyl-ACP held constant at 1 pM (Table 11). There was no significant difference 
between the Kmapp values for myristoyl-ACP or proHlyA for the S-tag and His«-S-tag 
HlyCs. Although the value for myristoyl-ACP and proHlyA increased for the 
Hist-S-tag HlyC enzyme, the increase in acyltransferase activity was due to the improved 
quality of the proHlyA preparations rather than differences in the specific activity of the 
two fusion proteins.
For the majority of the single-site mutations there was no significant change in the 
value of Km*" or Vm,.<pp for either myristoyl-ACP (Table 10) or proHlyA (Table 11).
This was not too surprising since through mutagenesis studies such as these it has become 
apparent that most proteins can tolerate single residue substitutions quite well (104). Of 
course the most interesting mutations were those that resulted in complete loss of 
function; G l 1 A, H23A, H23S, H23C, Y70G, and G85A. There were, however, two
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Table 10: KINETIC PARAMETERS OF MYRISTOYL-ACP FOR NATIVE 
AND MUTANT MS6-S-TAG-HLYCS*
Mutation V  «PP % of native Km*pp v  *pp» max % of native Vmax*pp
None 0.61±0.1 100 14.0±0.5 100
G11A NDb ND ND ND
G8SA ND ND ND ND
H23A ND ND ND ND
H23S ND ND ND ND
H23C ND ND ND ND
R24A 0.32±0.02 52 6.2±0.1 44
R87A 0.36±0.10 59 7.0±0.3 50
S20A 0.40*0.10 66 1.8±0.7 13
S58A 0.26±0.01 43 5.6±0.2 40
S76A 0.30±0.01 49 7.6±0.1 54
E67A 0.77±0.01 126 17.0±0.7 121
D86A 0.29±0.01 48 9.2±0.1 66
Y70G ND ND ND ND
Y70F 0.80±0.10 131 11.8±0.4 84
Y150G 0.97±0.10 159 4.2±0.2 30
Y150F 0.65*0.10 107 14.2±0.5 101
C57A 0.62*0.01 102 13.7±0.6 98
*Km*pp in pM, and Vimx*pp is pmol incorporaied/min. Kinetic parameters are apparent 
values for the particular conditions given including the concentration of the fixed 
substrate, proHlyA, which was 2pM. bKinetic parameters of mutant HlyCs without 
sufficient activity were not determined (ND).
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Table 11: KINETIC PARAMETERS OF PROHLYA FOR NATIVE AND 
MUTANT HISe-S-TAG-HLYCS*
Mutation V «PP % of native
N n
v  *PP▼ max % of native V imxipp
None 2.19±0.17 100 15.2 ±2.7 100
G11A NDb ND ND ND
G8SA ND ND ND ND
H23A ND ND ND ND
H23S ND ND ND ND
H23C ND ND ND ND
R24A 2.12±0.13 97 10.6±0.3 70
R87A 2.61 ±0.26 119 U.6±0.6 76
S20A 1.31±0.10 60 2.0±0.1 13
SS8A 1.43±0.15 65 7.13±0.3 47
S76A 2.39±0.20 109 12.5±0.5 82
E67A 1.89±0.13 86 15.0±0.5 99
D86A 1.78±0.10 81 10.5±0.3 69
Y70G ND ND ND ND
Y70F 1.89±0.13 86 15.0±0.5 99
Y150G 1.45±0.23 66 3.14±0.2 21
Y150F 1.71±0.06 78 12.6±0.2 83
C57A 2.20±0.17 100 14.6±0.6 96
'Km** in (iM, and V~.*pp is pmol incorporated/min. Kinetic parameters are apparent 
values for the particular conditions given including the concentration of the fixed 
substrate, myristoyl-ACP, which was IpM. ‘Kinetic parameters of mutant HlyCs without 
sufficient activity were not determined (ND).
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mutations that resulted in significant changes in the VmaXt,>p values for both substrates. 
Both the Y1S0G and S20A HlyCs produced Vm„ a,’p values for myristoyl-ACP and 
proHlyA that were significantly reduced compared to the wild-type enzyme.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 4 
DISCUSSION
All the proteins involved in rendering proHlyA toxic were highly purified except 
the proHlyA which was >90% pure; both intracellular proHlyA and secreted proHlyA 
served as substrates in the reaction. It is unlikely that an unrecognized HlyC-dependent 
acyltransferase activity could be present as a contaminant in each of these disparate 
proHlyA preparations. The role of HlyC as the acyltransferase was confirmed (15,105) 
by showing that the purified fusion protein was the single factor necessary in bringing 
about toxin formation in the presence of acyl-ACP and proHlyA. Furthermore, although 
HlyC and proHlyA may be produced in similar amounts in  vivo, the catalysis of the 
internal protein fatty acylation was a typical enzyme-substrate relationship. Catalysis 
ensued with less than stoichiometric amounts of HlyC relative to proHlyA and fatty acyl 
groups transferred. The specific activity of the enzyme isolated from the soluble portion 
of the cell lysate was approximately 300 times greater than the best renaturation achieved 
from inclusion bodies, and it had a roughly estimated turnover number of 4,450 
moles/min, a respectable enzymatic activity. The cell soluble extract HlyC would likely 
be more representative of the in  vivo enzyme catalyzing toxin activation than that from 
inclusion bodies. HlyC extracted from inclusion bodies was, however, much purer. 
Aggregation in inclusion bodies has been shown to be protein-specific, and, thus 
relatively pure proteins are extracted from the inclusion body state (106).
The acyltransferase assay was highly reproducible, quantifiable, and, as shown by 
fluorography and densitometric analysis, directly measured product formation. The
104
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erythrocyte lysis assay widely used to assess HlyA, and indirectly HlyC activity, is 
not an appropiate measurement of acyltransferase activity since the stoichiometry of 
HlyA toxin lysis remains unkown. Futhermore, lysis was shown not to be a good 
measure of HlyA formation because of the dependence of HlyA’s lytic ability upon the 
nature of the HlyA fatty acyl group rather than the quantity of HlyA (discussed below). 
The acyltransferase assay also enabled measurement of characteristics which might 
independently affect cell membranes and subsequently lysis such as ions, temperature, 
etc. on transacylation alone. Developing an HlyC assay system separate from toxin lysis 
is important for the study of the enzyme and its protein substrates. For example, Ca2+ has 
been shown to be required for binding the toxin to target cells (30, 31). In contrast, Ca2* 
alone among numerous ions investigated inhibited toxin acylation as measured by the 
direct assay. Ca2+ inhibition of transacylation likely arose from its effect on proHlyA 
conformation (34).
The effects of different fatty acyl groups acylating the toxin on the lytic abilities 
of the respective fatty acyl-toxins has not been previously addressed. Different acyl- 
ACP s varied in their efficacies as substrates for the acyltransferase while the acyl-toxins 
exhibited yet a dissimilar ranking of power as lytic agents. Neither the lytic response nor 
acyl donor capability of the respective acyl groups was accounted for by increases in 
hydrophobicity and membrane affinity associated with the addition of carbon groups to a 
fatty acyl chain (107). Acyl-ACP efficacies declined with increasing chain length; there 
was no such trend in the lytic behaviors of HlyA’s bearing different acyl groups. The 
introduction of double bonds into an acyl chain decreases its hydrophobicity and its 
affinity for membranes (107); no structural generalization was apparent, however,
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regarding acyl group unsaturation and behavior as an acyl-donor. The toxins acylated 
with 16 carbon chain length saturated and unsaturated fatty acids were present in 
different quantities but produced similar amounts of lysis. In contrast, the toxins acylated 
with 18 carbon chain length saturated and unsaturated fatty acids produced similar 
amounts of toxin and lysis. Perhaps distinct acyl groups favor separate characteristics 
such as toxin aggregatability and different efficiencies of membrane insertion which 
contribute to the overall lytic efficacy of a particular toxin. Additionally, the acylation of 
a protein may have a significant but as yet undefined effect on its higher order structure. 
Although acyl transfer is directly measured in the HlyC assay described herein, whether 
one or both of the proHly A acylation sites was acylated by each of the different acyl- 
ACP donors is not known. Welch and co-workers have shown that acylation at only one 
or the other of the two potential sites has differential effects on hemolytic activity (21, 
108). The different lytic efficacies of the HlyA’s bearing different acyl groups could 
stem, in part, from unequal acylation of the two potential acylation sites. Since the extent 
of lysis depends upon carbon chain length and unsaturation of the acyl-group, lysis 
without experimental qualification is not a valid measure of proHlyA activation. 
Furthermore, the identity of fatty acyl groups on HlyA produced in vivo are not known.
Acylation of proHlyA to form HlyA was more sensitive to fatty acyl-group 
structure than was lysis by the resulting HlyA, but fatty acids or fatty acyl-CoA’s had no 
effect on the acyltransferase reaction velocity in contrast to ACPSH which inhibited.
Thus fatty acyl groups per se were not recognized by HlyC while ACPSH was 
recognized. Large variations in the Km values of the various acyl-ACPs pointed to crucial 
structural differences among the various acyl-ACPs. These differences could be related
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to different acyl chain lengths fitting an HlyC acyl group binding site for acyl-ACP.
This hypothetical HlyC acyl group binding site likely operated secondary to protein-
protein recognition in view of the fact that fatty acids alone were not inhibitory.
Alternatively, slight but significant conformational variations among acyl-ACP’s cannot
$
be ruled out. NMR studies of ACPSH and octanoyl-ACP suggest that there are not large 
structural differences among the acyl-ACPs which served as acyltransferase substrates 
(109). Some degree of conformational variation among the acyl-ACPs studied is, 
however, established by their different migrations on conformationally sensitive non- 
denaturing PAGE in the presence of urea (110). The fatty acyl chain strengthens the 
native structure in proportion to the carbon chain length (110, 66). A dynamic structure 
illustrated as a model involving two conformers provides the best fit of NMR analysis of 
ACP structure (111). With such a structure, different fatty acyl groups may exert distinct 
transitions among conformers of the acyl-protein.
Recognition between acyl-ACP and HlyC was underscored by the demonstration 
of their binary complex through chemical cross-linking and by the appearance of an acyl- 
HlyC intermediate. That the acyl-enzyme intermediate is a step on the main pathway in 
the reaction sequence was shown by its disappearance upon proHlyA addition with the 
concomitant appearance of HlyA. It was not a non-reactive, dead-end product; it was a 
viable intermediate whose detection depended upon the lack of proHlyA, the acyl 
acceptor. Furthermore, the acyl-enzyme intermediate was able to catalyze the reverse 
reaction, transferring its acyl group to ACPSH. The formation of heterodimer, acyl- 
ACP-HlyC, shown by chemical cross-linking corroborated the HPLC demonstration that 
monomer was the active form of HlyC. The transfer of the acyl group from the acyl-
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enzyme to proHlyA was apparent, with no evidence of any heteromolecular 
complexes with proHlyA/HlyA. The lack of much variability among Vmu m  values 
while Km^’s varied extensively suggests that formation of the acyl-enzyme intermediate 
varies among acyl-ACP reactants and that acyl transfer from the acyl-enzyme to proHlyA 
proceeds at similar rates among acyl-enzyme species. The formation of the acyl- ACP- 
HlyC heterodimer, formation of an acyl-enzyme intermediate, and the fact that acyl-HlyC 
catalyzes the reverse reaction all support a substituted enzyme mechanism for the 
acyltransferase reaction.
The kinetic mechanism of HlyC was thoroughly investigated and the results were 
consistent with a uni uni iso uni uni ping pong kinetic mechanism where enzyme form F 
isomerizes (97). Scheme 1 summarizes the enzyme catalyzed reaction sequence in 
Cleland notation (772); F' and F represent the two isomers of the enzyme.
Scheme 1; Kinetic Mechanism of HlyC, acyl-ACP-proHlyA acyltransferase. 
Acyl-ACP ACPSH proHlyA HlyA
E <-* E«acyl-ACP <-> F-acyl <-* F-acyl <-> F-acyl«proHlyA <-> E
Inhibition patterns generated by the products with respect to the different substrates 
enabled more exact definition of the substituted enzyme kinetic mechanism.
Inhibition by the first product, ACPSH, with respect to both myristoyl-ACP and 
proHlyA gave primary plots indicative of uncompetitive inhibition; replots of the 
l/V IMX',ip values of the family of plots were, however, hyperbolic. Pure uncompetitive
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inhibition would show a linear replot while the curves continued to move apart as [I] 
increased. Instead the inhibition was a mixed-type in which K«, and Vmix changed by the 
same factor, but the displacement of the curves approached a limit as [I] increased giving 
a hyperbolic replot (86). In this situation, the product inhibitor combines with more than 
one enzyme form in alternate reaction sequences resulting in mixed-type inhibition, like 
that described generally by Cleland’s rule 3 (113,114) and in more detail by Segel (86). 
Scheme 1 shows that the release of the product ACPSH generated an enzyme species 
different from that to which myristoyl-ACP bound. The enzyme species to which the 
second substrate, proHlyA, bound also differed from the enzyme form that released (and 
bound) ACPSH because of the isomerization of the F species of the enzyme prior to 
binding proHlyA. Inhibition by product under these circumstances would be expected to 
be mixed-type (1 IS).
Inhibition by the second product, HlyA unambiguously showed competitive 
inhibition in both primary plots with either myristoyl-ACP or proHlyA as varied 
substrates at unsaturating levels of the other. Replots of the data from the two separate 
primary plots of HlyA inhibition were, however, quite dissimilar indicating different 
mechanisms of inhibition by HlyA for each of the two substrates. The tendency of HlyA 
to aggregate (76) placed an upper limit on the concentrations that could be examined in 
the HlyC assay. With respect to myristoyl-ACP, HlyA was a parabolic or two site 
competitive inhibitor, the sites are separate and independent of one another (87). Replots 
to calculate K; for a two site competitive inhibitor were not linear indicating that there 
were more than two independent inhibitor binding sites (87). Scheme 1 demonstrates that 
myristoyl-ACP and the product HlyA bind to the same species of enzyme thus predicting
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a competitive type of inhibition in accordance with Cleland’s rules that also predict 
the observed parabolic effect on replots upon binding of multiple inhibitor molecules 
U I3 ).
HlyA inhibition with respect to proHlyA, although showing primary plots 
diagnostic of competitive inhibition, gave rise to replots quite different from parabolic or 
linear competitive inhibition. Both the hyperbolic replot of Kffl*pp/V inax*n> against [I] and 
the leveling-off of v versus [I] curves indicated partial competitive inhibition (Figures 19 
(inset) and 20B). Scheme 1, however, shows that, in contradiction to competitive 
inhibition, HlyA and proHlyA bind to different enzyme forms ( / 13). Segel (90) 
describes multiple situations which give rise to mixed-type inhibition. Included is a 
circumstance that resembles partial competitive inhibition, but it is not. It is really a form 
of mixed-type inhibition, and it is a specific example of a Cleland rule 3 situation where a 
compound reacts with two different enzyme forms (sites) causing different effects which 
result in hyperbolic replots (113). According to the model presented by Segel (116) 
which is diagramed in Figure 33, the mixed-type inhibition in this instance arises from 
the hypothetical existence of two separate types of sites for inhibitor binding which are 
mutually exclusive. The model involves the interplay of two separate and differently 
behaving inhibitor binding sites and yet another binding site, the substrate binding site 
(Figure 33, E). Neither inhibitor binding site is the catalytic site (substrate binding site). 
There are, however, electronic or conformational responses within the enzyme upon 
occupation of either inhibitor binding site by inhibitor which cause the following 
behaviors in the remaining two sites, the alternate inhibitor binding site and the substrate 
binding site: One inhibitor binding site is a noninhibitory site that, when occupied,
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noninhibitory site catalytic site
inhibitory site
Figure 33: Mixed-type inhibition model of binding sites, possible occupancies, and 
resulting enzyme forms in HlyA product inhibition with respect to proHlyA. 
Abbreviations and symbols are as follows: I, inhibitor; S, substrate; El41, inhibitory 
enzyme-inhibitor complex; IE, noninhibitory enzyme-inhibitory complex, ES, enzyme- 
substrate complex; IES, noninhibitory inhibitor-enzyme-substrate complex. Model 
adopted from Segel (116).
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distorts the second inhibitor binding site and prevents its binding of inhibitor, while 
substrate binding (and subsequent activity) is unimpaired (Figure 33, IE and IES). Thus 
inhibition can only be partial because all inhibitor binding does not result in inhibition. 
The second inhibitor binding site, when occupied, causes distortions of both the 
noninhibitory inhibitor binding site and the substrate binding site (Figure 33, El*). It 
prevents substrate from binding to the catalytic site (pure competitive action). The model 
gives rise to a mixed-type inhibition because in one instance inhibitor and substrate (IES) 
can bind simultaneously to the enzyme while in another instance only inhibitor (E l*) or 
substrate (ES) can bind to the enzyme. This mixed-type inhibition appears as partial 
competitive inhibition and cannot be distinguished by kinetics from a single-site model of 
partial competitive inhibition.
The steady state kinetics, the demonstration of a reactive acyl-enzyme 
intermediate, and the demonstration of the reversible first half reaction all supported a 
ping pong kinetic mechanism for HlyC. Distinctions among several different types of bi 
bi ping pong mechanisms were made by analyses of the product inhibition patterns with 
respect to the various substrates. The results of these studies of the internal protein 
acyltransferase reaction are compatible with a uni uni iso uni uni ping pong kinetic 
mechanism where enzyme form F isomerized.
Once the kinetic mechanism was defined, efforts were turned to elucidating the 
chemical mechanism of the enzyme. Chemical modification of HlyC suggested the 
possibility of histidines, tyrosines, and arginine residues being involved in HlyC catalysis 
while ruling out the possibility of any crucial serines, cysteines, and, indirectly, lysine 
residues. Overall, data from chemical modification and site-directed mutagenesis
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experiments agreed very well. For example, the CS7A mutant possessed wild-type 
acyltransferase function, and HlyC was insensitive to sulfhydryl modifying reagents.
Also, treatment of the enzyme with TNM at pH 6.0 did not inactivate the enzyme, 
conditions that result in thiol oxidation (777). Mutation experiments revealed that Ser 20 
and 76 were necessary for wild-type function. This finding did not contradict the 
chemical modification data showing no inhibition of acyltransferase activity by PMSF 
and AEBSF, since PMSF and AEBSF tend to react with unusually reactive serines and in 
some cases do not react with serines known to function as active site nucleophiles. For 
example, the malonyl-/acetyltransferase has an active site serine contained within the 
GXSXG motif characteristic of many serine active site esterases (775), but the enzyme is 
not inhibited by PMSF.
HlyC was very sensitive to DEPC modification and evidence was presented to 
suggest specific histidine modification. Inactivation of enzyme was enhanced at pH 6.0 
which suggested histidine modification, since DEPC prefers unprotonated nucleophiles 
(79). Further evidence included the reactivation of DEPC modified HlyC by 
hydroxylamine treatment and the spectral evidence of N-carbethoxyhistidine formation 
with lack of ethoxyformylation of tyrosine. The importance of the modified histidine(s) 
was demonstrated by substrate protection experiments indicating the modified residue is 
located within or near the active site of HlyC. The fact that acyl-ACP protected HlyC 
from DEPC modification; whereas, ACPSH offered no protection could be attributed to a 
histidine lying within an acyl group binding site in the enzyme. Also, according to the 
predicted uni uni iso uni uni ping pong kinetic mechanism of HlyC, ACPSH binds to a 
different form of the acyltransferase than acyl-ACP; therefore, lack of protection could
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simply be lack of protein-protein interaction of ACPSH with a specific form of the 
enzyme.
Although DEPC could modify any of the 6 histidines of HlyC, His 23 was chosen 
for site-directed mutagenesis experiments because of its conservation among the RTX 
toxin acyltransferases. Mutation of conserved His 23 to alanine corroborated the 
importance of histidine modification by DEPC. In addition to H23A, the H23S and 
H23C mutants were totally inactive. While serine and cysteine residues could function as 
nucleophiles during acyl-enzyme intermediate formation, they typically do not function 
in acid-base catalysis. Lack of activity for the H23S and H23C mutants does not rule out 
the possibility of His 23 functioning as the active site nucleophile since conversion of His 
23 to a serine and cysteine residue could disturb the position and orientation of the active 
site. In some cases, substitution of the active site nucleophile with a second nucleophilic 
side chain is successiveful, but other times only minimal activity is retained. For 
example, the plant acyl-ACP thioesterase retains >60% activity upon mutation of the 
nucleophilic cysteine to a serine residue {119), whereas, replacement of the active serine 
of the malony-/acetyltransferase with cysteine results in retention of ~l%  activity (118). 
Such a small retention of activity for H23C or H23S would not be detectable using the 
current HlyC assay system.
Inactivation of HlyC by TNM suggested an important tyrosine(s) and this was 
further evident by a pH dependency of TNM modification at pH 8.0, as well as spectral 
data showing formation of 3-nitrotyrosine. Chemical data suggesting a reduction in 
acyltransferase activity due to tyrosine modification was confirmed by mutating 
conserved Tyr 70 and ISO to glycines since mutational studies showed both residues were
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critical for wild-type enzyme function. HlyC contains 7 tyrosines, 2 being fully 
conserved, and 3 more conserved for hydrophobicity. TNM could potentially modify all 
of HlyC’s tyrosines, but only the function of Tyr 70 and 150 were addressed in the site- 
directed mutagenesis studies presented here since this work focused on conserved 
residues among the different RTX toxin acyltransferases. Substitution of a tyrosine to a 
glycine residue results in an amino acid change with the greatest decrease in 
hydrophobicity, but still allows for flexibility in protein secondary structure (120). 
Changing either Tyr 70 or Tyr 150 to a glycine residue did not predict changes in HlyC 
secondary structure. Comparison of quickly diluted and refolded HlyCs allowed further 
characterization of mutant enzymes helping to suggest roles for various residues. The 
20% increase upon slowly refolding Y150G most likely results from conformational 
changes, suggesting Tyr 150 has a role in protein conformation and/or stabilization.
Decreases in activity observed with HlyC mutants Y70G and Y150G could easily 
be recovered by replacing the glycine with a phenylalanine restoring hydrophobicity and 
showing the lack of need for the -O H  group. That an important tyrosine whose -OH  
group was not essential was also shown by chemical modification experiments, since 
HlyC acyltransferase activity was insensitive to acetylation of the tyrosyl -OH by NAI 
and acylation by DEPC (pH 8.0), but inactivated by TNM nitration of the tyrosyl 
phenolic ring (pH 8.0). As with DEPC inactivation of HlyC, the importance of a tyrosine 
residue(s) was underscored by protection experiments from TNM. Inactivation of 
enzyme by TNM in the presence of acyl-ACP was unsuccessful but in the presence of 
ACPSH inactivation proceeded as ususal. Perhaps one of the conserved tyrosine residues 
is necessary for providing a hydrophobic environment within an acyl group binding site
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in HlyC for the acyl-ACP substrate. This may explain chemical cross-linking data 
since Y70G and Y150G formed low levels of heterodimer suggesting a role in substrate 
recognition. Also, mutation of the conserved tyrosines could lead to an overall 
conformational change decreasing acyl-ACP substrate recognition unrelated to acyl 
group recognition. It would be of interest to determine if  ACPSH cross-links to a greater 
degree to Y70G and Y150G HlyC mutants, as compared to acyl-ACP.
HlyC contains 6 arginines with 2 conserved among the 13 acyltransferases. An 
important arginine(s) was suggested by PG modification and confirmed by mutation of 
conserved positively charged Arg 24 and Arg 87 to alanines. Like the Y1S0G mutant, 
R87A showed an increase in activity upon slow renaturation, in this case an increase of 
-70% as compared to HlyC refolded by quick dilution. This data implied that Arg 87 is 
important in protein conformation. Reduction in activity seen with the R24A and R87A 
mutations could be a result in the removal of positive charge or possibly the change in 
residue size. Further mutations will be necessary to determine the role of these conserved 
residues. Acyl-ACP protected HlyC from PG modification, but to a lesser extent than 
found in TNM and DEPC modification experiments. Also for the first time ACPSH 
offered marginal protection. Taken together the protection experiments indicate that the 
modified arginine(s) is less likely to be influenced by the acyl chain of the acyl-ACP 
substrate and therefore less likely to be involved at the catalytic site. It seems that Arg 24 
and 87 are most likely involved in a protein structural role rather than in the catalysis. 
Perhaps the positively charged residues participate in binding to the negatively charged 
acyl-ACP substrate, since ACPSH can protect HlyC from PG modification, albeit at
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lower levels. This is partially supported by chemical cross-linking data since R24A 
produces less heterodimer compared to wild-type HlyC control.
Mutation of the only conserved acidic residues E67 and D86 to alanines gave 
mixed results. E67A functioned at wild-type levels, and D86A showed a decrease in 
activity. Finally conserved glycines 11 and 85 were mutated to alanines with both 
mutations leading to non-functional HlyCs, most likely arising from changes in protein 
conformation since glycine residues are typically not involved at the catalytic site. 
Whether or not a single-site amino acid change within HlyC could change the acyl group 
specificity of the acyl-ACP substrate was not addressed. Although this seems unlikely, 
since myristoyl-ACP was used in comparing mutant and native enzyme function, a 
change in the acyl chain specificity for a mutant enzyme as compared to the wild-type 
control would lead to misinterpretation of the results. Such an instance has been reported 
in which mutating a single amino acid of the lysophosphatidate acyltransferase (LP AT) 
resulted in changes in acyl-CoA substrate specificity (121).
Cross-linking experiments and acyl-enzyme intermediate formation by mutant 
HlyCs proved to be valuable experiments for suggesting roles of amino acid residues in 
the acyltransferase mechanism. For example, the H23A, H23S, and H23C mutants were 
incapable of forming acyl-enzyme intermediate, but all cross-linked at wild-type levels 
with acyl-ACP. These data imply His 23 is not necessary for acyl-ACP substrate 
binding, but critical for the formation of acyl-HlyC, the first half of the proHlyA 
acylation reaction. All single site mutations gave rise to HlyCs that cross-linked to acyl- 
ACP to some extent except for one, G85 A. No mutants formed acyl-enzyme 
intermediate without cross-linking to acyl-ACP, suggesting that heterodimer formation is
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a step along the pathway to acyl-enzyme formation. Upon examining acyl- 
intermediate formation for the various HlyCs, it was found that several enzymes 
produced an acyl-HlyC dimer, something not seen with the wild-type acyltransferase.
Determination of the kinetic parameters for the mutant enzymes showed little 
difference from the wild-type acyltransferase. There were, however, significant changes 
in VmM*"’ values for both acyl-ACP and proHlyA substrates when the S20A or Y150G 
mutants were the source of enzyme, implying that Ser 20 and Tyr ISO are involved in the 
the acyl transfer reaction. This, however, does not rule out a conformational role for Ser 
20 and Tyr ISO.
With the data from chemical modification and site-directed mutagenesis 
experiments one can conclude that HlyC contains several residues that are critical for 
acyltransferase function, an essential histidine; His 23, an essential tyrosine; Tyr 70, and 
two essential glycines; Gly 11 and 8S. The remainder of the mutations, while in some 
cases significantly affecting enzyme function, were tolerable since HlyC was not 
completely inactivated. O f the residues listed above only His 23 and Tyr 70 could have 
an acyl group covalently attached to their respective side chains. Since replacement of 
the two conserved tyrosines with phenylalanines restored enzyme activity, Tyr 70 cannot 
be the site of HlyC acylation in acyl-intermediate formation. This leaves only His 23.
As discusssed earlier, based upon protein sequence comparison data, HlyC is a 
unique acyltransferase. This follows with the work presented here since HlyC appears to 
contain no essential cysteines or serines needed for acyl transfer, which is not the case for 
enzymes typically involved in these sort of reactions. For many acyltransferases, 
esterases, lipases, and proteinases a histidine residue functions in an acid-base role with a
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second amino acid, a serine or cysteine, functioning as the nucleophile. Upon site- 
directed mutagenesis of these histidine residues, the enzymes become very inefficient, 
but, generally, complete loss of activity is seen only when the serine or cysteine residues 
that function as nucleophiles in the chemical mechanism are mutated {122). The HlyC 
acyltransferase is notable in that it loses all detectable activity upon mutation of the single 
conserved histidine residue, but the enzyme retains activity, although impaired in some 
instances, upon mutation of conserved serines or cysteine residues.
HlyC contains I cysteine and 11 serines. Since the CS7A mutant retained native 
acyltransferase activity this removes the possibility of an -SH group functioning as a 
nucleophile. Although all of the serine residues were not mutated, with the chemical 
modification and mutagenesis data presented here it would seem unlikely that HlyC 
contains an active site serine since the remaining 8 serines are not conserved among the 
RTX toxin acyltransferases. To date, there have been no enzymes shown to possess a 
histidine functioning as the active site nucleophile giving rise to an acyl-imidazole 
intermediate. However, a histidine residue has been shown to act as a nucleophile 
forming an acyl-antibody intermediate in a reaction catalyzed by an antibody {123) and 
histidine 1106 of the C4B isotype of human complement forms an acyl-imidazole 
intermediate after attacking an internal thioester located within the protein {124,125). 
With the evidence presented above it is feasible that His 23 functions as a nucleophile in 
the transfer of acyl groups from acyl-ACP to proHlyA. In order to clarify further the 
chemical mechanism of HlyC, additional studies will be necessary.
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